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3. ABSTRACT 
Atopic dermatitis (AD) is a common pruritic skin disease with prevalence rates up to 20 % 
in children and 3 % in adults. Skin barrier defects combined with modified immune 
responses of the innate and adaptive immune system activate complex pathophysiological 
pathways that are involved in the development of this disease. AD is characterized by 
acute flare-ups as well as chronic eczematous pruritic skin lesions and dry skin. It is 
crucial to clarify the mechanisms underlying AD in order to devise mechanism-based 
therapeutic approaches. However, the immunological mechanisms participating in AD are 
far from being completely understood. This thesis investigates mechanisms believed to be 
involved in atopic skin inflammation by utilizing an AD-like experimental animal model 
as well as human patients. The AD-like mouse model was also used to examine the 
model's suitability for evaluating topical medications for treating AD. In addition, this 
thesis investigates some of the mechanisms in the so-called atopic march. 
 
Results highlight new molecular mechanisms involved in AD and the atopic march. 
Microbial superantigen, derived from Staphylococcus aureus exacerbates the allergen-
induced skin inflammation mostly by a mixed Th1/Th2 type inflammation in the presence 
of both CD8
+ 
and CD4
+ 
T cells and elevated IgE concentrations. This kind of severe 
inflammation, induced by allergen and superantigen in the murine skin, was declined with 
topical corticosteroid and calcineurin inhibitor. According to these results, this AD model 
is both reproducible and suitable for testing novel treatment options in AD. 
 
Finally, a recently characterized Th2-promoting cytokine, IL-33, and its receptor, ST2, 
were investigated in murine models of AD and allergic asthma as well as in human AD 
and in different cell models. The results obtained from ST2-/- mice suggest that the IL-
33/ST2 pathway can regulate innate immune responses and CD8
+
 T cell mediated 
responses in the skin and in lung tissue. However, ST2 appeared to be dispensable for the 
development of Th2 response in the sensitized skin, whereas it was the main inducer of 
Th2 cytokines in asthmatic airways. Together, these results obtained from the murine 
model of AD and from the skin of patients with AD reveal new molecular mechanisms 
involved in AD. 
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4. INTRODUCTION 
The allergic or atopic diseases can be clinically manifested as allergic rhinitis, allergic 
asthma, food allergies, urticaria, anaphylaxis and atopic dermatitis (AD). The term allergic 
implies not only that the patient is sensitized but also that the allergen contributes to the 
disease or symptom. A susceptibility to become IgE-sensitized to environmental allergens 
is essential for atopy, and both genetic and environmental factors contribute to this 
predisposition. 
 
AD is a common skin disease usually beginning in early childhood. It is characterized by 
immune dysregulation and epidermal barrier defects. The majority, 50-75 %, of patients 
with severe AD develop allergic asthma or rhinitis later in life (Spergel, 2010). Recent 
research in the field of allergic diseases, especially AD has focused on the epidermal 
barrier defects and on epithelial-derived cytokines, which might serve as an early link to 
promote the Th2 type inflammation in the skin. In addition, bacterial colonization may 
vary in atopic and non-atopic individuals, e.g. patients with AD suffer from increased 
colonization of Staphylococcal enterotoxin B (SEB)-producing strains of Staphylococcus 
aureus. The combination of epidermal barrier defects, bacterial colonization, and adaptive 
immune responses to normally harmless proteins as well as genetic predisposition are 
usually associated with the manifestation of AD. 
 
The recent demonstration of loss-of-function mutations in the filaggrin (FLG) gene has 
highlighted a novel major predisposing factor for AD (Morar et al., 2007; Palmer et al., 
2006; Smith et al., 2006; Weidinger et al., 2006). Thus, barrier defects may facilitate the 
penetration and sensitization to environmental allergens and microbes. Moreover, patients 
carrying variations of FLG gene and suffering from early onset and rather severe AD, 
display the highest risk to develop allergic asthma. This also supports the so-called atopic 
march, which is characterized by the progression of AD to asthma and allergic rhinitis 
later in life. 
 
Epithelial-derived cytokines, including interleukin (IL)-33, thymic stromal lymphopoietin 
(TSLP) and IL-25 are believed to have a critical role in the pathogenesis of AD and 
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allergic asthma. A recent genome-wide association study (GWAS) detected a genetic 
association of the genes encoding IL-33 and ST2 with asthma (Moffatt et al., 2010). 
Moreover, a genetic polymorphism within the ST2 gene region has been reported to carry 
a strong association with AD (Shimizu et al., 2005). 
 
The aim of this thesis was to investigate some of the triggering factors in AD and the  
immunological mechanisms related to AD and atopic march. The effects of S. aureus-
derived superantigen were investigated in an experimental model of AD. The current 
topical treatment options in AD are corticosteroids and calcineurin inhibitors. However, 
better topical medications are needed, and therefore in this thesis the murine model of AD 
elicited by repeated allergen and SEB-exposures was evaluated for its ability to evaluate 
new topical treatment options and their mechanisms. Finally, the expression profiles of IL-
33 and ST2 after external triggering factors were investigated in experimental AD and in 
human AD, and the functional role of ST2 was determined in the murine model of AD and 
in allergic asthma. 
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5. REVIEW OF THE LITERATURE 
5.1 Immunity 
The innate immune system is interposed between the external environment and the 
internal acquired immune system. The microorganisms that are encountered daily in the 
life of a normal healthy individual only occasionally evoke any observable disease. Most 
of the microbes such as bacteria, viruses, fungi and parasites are detected and destroyed 
within minutes to hours by defence mechanisms that are part of the innate immunity 
system. Should a pathogen be able to breach the defence line of innate immunity, then 
adaptive immunity is activated. Although non-specific innate immunity and antigen-
specific adaptive immunity are often considered as separate entities, there is extensive 
cross-talk between innate and adaptive immune responses. Their dual action is important 
in combating the diverse array of microorganisms targeting the host throughout his/her 
life. 
5.1.1 Innate immunity 
Innate immunity represents the first line of defence against many microorganisms and is 
essential for the control of common infections. The innate immune system senses 
evolutionary conserved structures present in microbes, which makes possible effective 
destruction of many millions of species of bacteria, fungi, parasites and viruses. The innate 
immune system acts principally within the barrier tissues (skin, gut and airways), where its 
major function is host defence against infection. The innate immune system can be divided 
into three important effector mechanisms that promote the rapid removal of microbes: the 
professional phagocytes, the complement system, and the antimicrobial peptides (AMPs) 
(Bardoel and Strijp, 2011). 
 
Cells of the innate immunity, phagocytes, granulocytes, innate immune lymphocytes and 
epithelial cells express germline-encoded pattern recognition receptors (PRRs) that detect 
pathogen-associated molecular patterns (PAMPs) (Akira et al., 2001; Janeway and 
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Medzhitov, 2002) or danger-associated molecular patterns (DAMPs)(Lotze et al., 2007; 
Matzinger, 2002; Rubartelli and Lotze, 2007). DAMPs are molecules released by host 
cells that are injured or produced by host cells during inflammatory or immune responses 
(Minnicozzi et al., 2011). Several families of PRRs have been described, including, Toll-
like receptors (TLRs) retinoic acid-inducible gene-1 (RIG-1)-like receptors (RLRs), 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and DNA and 
RNA receptors. The effective sensing of PAMPs rapidly triggers host immune responses 
via activation of signalling pathways that terminate in the induction of inflammatory 
responses and finally in the eradication of pathogens. 
 
Approximately 30 proteins in the blood form a proteolytic cascade called the complement 
system. This is activated either directly by pathogens or indirectly by pathogen-bound 
antibody triggering a cascade of reactions on the surface of the pathogen and which 
generate active components with many effector functions. Activation occurs via three 
separate pathways that differ in their mode of recognition, but all converge at one central 
step: the cleavage of complement component C3. The activation of C3 results in the 
deposition of C3b molecules on the microbial surface and this signifies the microbe for 
efficient removal by phagocytes (opsonization). Further downstream, the complement 
cascade C5 is split into C5a and C5b. C5a attracts phagocytes to the site of infection, and 
C5b is the first component of the complex, which can itself lyse certain gram-negative 
bacteria (Sjoberg et al., 2009). 
 
One primitive innate defence mechanism is gene-encoded AMPs. They are synthesized as 
precursors and processed by specific proteases into mature, active forms either before or 
after secretion. These molecules can directly recognize microbial structures and lyse the 
cell membrane of the micro-organism. There are many different AMPs, with a great 
variety of physical and chemical characteristics. Antimicrobial peptides protect mucosal 
and dry epithelial surfaces of all multicellular organisms and they are also found in 
insects, which lack adaptive immunity. More than 500 different AMPs have been 
discovered in organisms from insects to humans. Two major classes of antimicrobial 
peptides in mammals have been described: defensins and cathelicidins (Zasloff, 2002). 
Defensins and cathelicidins perform several functions. They preserve epithelia, as in the 
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case of skin. In other settings, such as in the moist airways, the gastrointestinal tract, and 
the urinary tract, they are also secreted into the epithelial surface, where they create a 
barrier that is chemically lethal to microbes. Certain AMPs can even promote the 
epithelial growth and angiogenesis and attract immature dendritic cells and T lymphocytes 
to the site of an infection. Recent observations indicate that altered production of AMPs in 
the skin maybe involved in the pathogenesis of psoriasis and atopic dermatitis: 
Cathelicidins and defensins are strongly induced in psoriatic skin in comparison to normal 
skin, whereas the induction of antimicrobial peptides is much lower in atopic dermatitis 
lesions (Gallo and Nakatsuji, 2011). 
 
The cells of the innate immune system arise from common myeloid progenitors and 
include macrophages, granulocytes, mast cells and dendritic cells. Moreover, epithelial 
cells and several types of innate lymphocytes, including γδT cells, natural killer (NK) and 
natural killer T (NKT) cells participate in innate immune responses (Minnicozzi et al., 
2011). Epithelial cells are non-immune cells which can support the function of the 
immune cells. They express PRRs and function not only as a barrier, but also as a 
regulator of innate and adaptive immune responses (Bulek et al., 2010). Macrophages 
reside in almost all tissues and represent the mature form of monocytes, which circulate in 
the blood and continually migrate into tissues in order to differentiate. They engulf and 
kill invading microbes and are therefore important in the first line of defence in innate 
immunity. In addition, macrophages are fully functional antigen-presenting cells capable 
of activating naïve T cells (Mosser and Edwards, 2008). Neutrophils are the most 
abundant circulating cells in innate immune responses. They can rapidly recognize and 
take up microbes by phagocytosis and they efficiently destroy them by transferring them 
first to intracellular vesicles where they encounter degradative enzymes and other 
antimicrobial substances (Nordenfelt and Tapper, 2011; Summers et al., 2010). 
Eosinophils and basophils are less abundant than neutrophils, but like neutrophils they 
have granules containing enzymes and toxic proteins. Eosinophils and basophils are 
thought to be important in the defence against parasites, which are too large to be ingested 
by macrophages or neutrophils. They also contribute to allergic inflammation (Bochner 
and Gleich, 2010). Mast cells are derived from hematopoietic stem cells but mature 
locally, often residing near to those surfaces exposed to pathogens and allergens, such as 
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mucosal tissues and the connective tissue with its surrounding blood vessels (Abraham 
and St John, 2010). Dendritic cells are considered to be professional antigen presenting 
cells (APCs), based on their capacity to trigger the differentiation of antigen-specific 
effector T cell from naive T cell and therefore form a link between innate and adaptive 
immunity (Shortman and Liu, 2002). 
5.1.2 Adaptive immunity 
Adaptive immunity depends upon lymphocytes, which provide long-lasting immunity 
after exposure to either a disease or to vaccination. The adaptive immune system of 
vertebrates adopts efficient mechanisms of somatic diversification to generate unlimited 
repertoires of structurally diverse antigen receptors that are clonally expressed by 
lymphocytes. Clonal selection of lymphocytes with diverse receptors followed by clonal 
deletion of those lymphocytes that are potentially self-reactive are the central principles of 
adaptive immunity. The other central characteristic of adaptive immunity is the antibody, 
which is the secreted form of the B-cell receptor. B cells can also express their antigen 
receptors on their cell surface. Antigen receptors of T cells are always cell-surface bound. 
5.1.2.1 Antigen presentation 
An adaptive immune response begins when a pathogen is ingested by an immature 
dendritic cell in the infected tissue. These tissue-resident dendritic cells migrate through 
the lymph to the regional lymph nodes (LNs) where they interact with circulating naïve 
lymphocytes. T cells that have left the thymus enter the bloodstream and circulate between 
the lymphoid organ and blood, until they encounter their specific antigens in peripheral 
lymphoid organs, where the adaptive immune response is initiated (Murphy, 2012).  
 
Dendritic cells are critical in the initiation of inflammatory responses. In addition to 
antigen uptake and presentation, these cells link the innate and adaptive immunity 
systems, cause T cell differentiation and stimulate other lymphocytes (Steinman, 2012). 
During migration to local lymphoid tissue, DCs mature into cells that are effective at 
presenting antigens and express co-stimulatory molecules. At least two main families of 
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DCs have been identified in the skin: The plasmacytoid DCs (pDCs) and myeloid DCs 
(mDCs) which are further divided into two main subpopulations, epidermal Langerhans 
cells (LCs) and inflammatory dendritic epidermal cells (IDECs). pDCs are mainly 
responsible for the defence against virus, whereas LCs are considered to play a major role 
in the homeostasis within the immune response. IDECs are believed to have a major role 
in the generation and maintenance of inflammation through their production of 
proinflammatory cytokines (Shortman and Naik, 2007). mDCs also express the high-
affinity receptor for IgE and therefore mediate inflammatory reactions in IgE-mediated 
disease conditions including AD. 
 
Peptides on the cell surface of APCs are presented to CD8
+
 T cells and CD4
+
 T cells by 
MHC class I and MHC class II molecules, respectively. MHC class I molecules are 
expressed by all nucleated cells and present protein fragments of cytosolic and nuclear 
origin. MHC class II molecules are primarily expressed by professional APCs, such as 
DCs, macrophages and B cells and they bind to peptides that are derived from exogenous 
proteins degraded in the endocytic pathway. A link, termed cross-presentation, exists 
between the two pathways. Cross-presentatition is essential for the initiation of immune 
responses to viruses that do not infect antigen-presenting cells (Neefjes et al., 2011). 
 
When naïve T cells encounter cognate peptide/MHCII molecules on activated DCs, they 
undergo clonal expansion and differentiation into effector T cells. These effector CD4
+
 T 
cells can differentiate into Th1 or Th2 cells that migrate to inflamed non-lymphoid sites of 
antigen deposition or infection and start to produce cytokines. The number of effector cells 
peaks about one week after the naïve cells first encounter the peptide/MHC. After 
reduction of the inflammation, about 90 % of the effector cells die, leaving a residual 
population of memory T cells (Taylor and Jenkins, 2011). The memory T cells that reside 
at barrier tissues, such as skin, gut and lung, provide the first line of defence against 
subsequent infection. Memory T cells can also be located in LNs, spleen, blood and other 
nonlymphoid tissues.  
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5.1.2.2 Lymphocytes 
All adaptive immune responses are mediated by lymphocytes, which bear variable cell 
surface receptors for antigen. There are two main classes of lymphocytes: thymus-derived 
T lymphocytes (T cells) and bone-marrow-derived B lymphocytes (B cells). 
5.1.2.2.1 T cells 
T cells develop in the thymus from common lymphoid progenitors originating from the 
bone marrow. Subsequent differentiation of the expanded pool of T cell progenitors or 
pro-T cells in the thymus involves an antigen-independent process in which a coordinated 
series of genomic rearrangements leads to the creation of functional genes encoding the α 
and β or γ and δ chains of the TCR. Gene-segment rearrangements are productive if they 
do not introduce stop codons and give rise to a gene encoding a full-length TCR protein. 
Productive rearrangement of two TCR genes leads to surface expression of αβ or γδ TCR. 
Two major T cell lineages arise: the minority population of γδ CD3+ T cells, which lack 
CD4 or CD8, and the majority population of the αβ T cell lineage, which develop from 
pre-T to double positive T cells expressing both CD4 and CD8. Further differentiation of 
these double-positive cells to single-positive T cells is regulated by both positive and 
negative selection events involving antigens and molecules of the MHC. Positive selection 
occurs when the TCR of double-positive T cells binds with low affinity to self-MHC. 
Double positive cells bearing a TCR, which does not bind to self-MHC, are eliminated. 
Conversely, negative selection is exerted on double-positive T cells, which bind with very 
high affinity to self-MHC/peptide, ensuring that autoreactive T cell precursors are not 
matured. Finally double-positive T cells that pass both positive and negative selection 
mature into CD8
+
 single-positive or CD4
+
 single-positive T cells (Bonilla and Oettgen, 
2010). 
 
Resting naïve CD8
+
 T cells differentiate into cytotoxic effector cells after encountering 
pathogen-loaded DC bearing the MHC class I molecules, in the LN. Instead of antigen-
rich macrophages, naïve CD8
+ 
T cells favour the DC population to deliver the first contact 
and the start of differentiation (Zhang and Bevan, 2011). A further interaction with DCs 
and CD8
+
 T cells occurs at the site of infection finally leading to protection of host by 
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killing the infected cell with minimal tissue damage. Proinflammatory cytokine IL-12 
plays a key role in the differentiation of CD8
+
 effector T cells. Several cytokines are 
important in the terminal differentiation of CD8
+ 
effector T cells through the induction of 
transcription factors. IL-2 signalling activates the transcriptional repressor Blimp-1 
expression, which co-operates with other transcription factors, such as T-bet, Eomes, Id1, 
Id2 and Id3 to promote CD8
+
 T cell effector differentiation and migration to the peripheral 
site (Zhang and Bevan, 2011). Other cytokines involved in CD8
+
 effector cell 
differentiation are IL-21 and IL-27. When effector CD8
+ 
T cells migrate to peripheral 
sites, they can mediate their effector function by producing cytokines IFNγ and TNFα. 
Recent data has demonstrated that also IL-10 can be secreted from CD8
+ 
T cells in a viral 
infection model. It is suggested that IL-10
+
CD8
+
 T cells are superior killers and produce 
normal to high amounts of granzyme B, IFNγ and TNFα. Therefore, in addition to killing 
infected cells, CD8
+
 T cells can also serve a regulatory role in preventing tissue injury by 
secreting the immunosuppressive cytokine, IL-10. 
 
CD4
+
 T cells recognize the peptides bound to MHC class II molecules and are divided into 
at least four major lineages: Th1, Th2, Th17 and regulatory T cells (Treg). Also Th22 cells 
have been described, but molecularly those are related to Th17 cells (Waisman, 2011). 
Transcripton factors are distinct in these CD4
+
 T cell populations and they determine the 
cells differentiation into T helper cells and Treg cell subsets. The Th2 cell pathway is 
linked to IL-4–STAT6 and GATA-3, whereas the Th1 cell pathway is linked to IFNα, β or 
γ–STAT1, IL-12–STAT4 and T-bet. The Th17 pathway is linked to TGFβ plus IL-6/IL-
21/IL-23–STAT3 and RORγt/RORα. STAT5 and Foxp3 act in regulatory T cells. 
Additional CD4
+
 T cell subsets, including Th9 and T-follicular helper (Tfh) cells have been 
described, although they remain less well characterized. Th9 and Tfh subsets have been 
recently linked to STAT6/PU.1 and STAT3/Bcl6, respectively (Balasubramani et al., 
2010) (Fig 1). 
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Figure 1  T helper subsets and their transcripton factors, differentiation and effector cytokines. 
 
Th2 cells are specialized for B cell activation and secrete B cell growth factors IL-4, IL-5 
and IL-13. Th2 cells are critical in the clearance of extracellular pathogens, such as 
bacteria and a variety of parasites, and are also involved in allergic reactions. The 
principal membrane-bound effector molecule expressed by Th2 cells is CD40 ligand, 
which binds to CD40 on the B cell and induces isotype switching (Murphy, 2012). Th1 
cells secrete IFNγ and TNFα and are specialized in their ability to activate macrophages 
that are infected or have ingested pathogens. Th17 cells produce IL-17, IL-21 and IL-22 
(Commins et al., 2010).  
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Recent findings in T cell research have revealed that T cells might be plastic. Th2 cells 
can start to produce IFNγ without losing their capacity to produce IL-4, this being 
consistent with the co-expression of GATA3 and T-bet, although their expression of 
GATA3 is lower than in "conventional" Th2 cells (Hegazy et al., 2010). Another two 
studies demonstrated that Th17 cells are highly plastic and tend to re-differentiate into Th1 
cells in vivo (Hirota et al., 2011; Kurschus et al., 2010). Different T cell subsets play a 
significant role in certain disease conditions. The numbers of Th2 and Th1 cells are 
markedly increased in many inflammatory diseases, such as AD and allergic asthma, 
whereas those of Th17 are increased in various autoimmune conditions and cancer (Wilke 
et al., 2011). In contrast, the absence of regulatory T cells causes severe systemic 
autoimmunity. 
 
5.1.2.2.2 B cells and immunoglobulins 
B cells arise from hemopoietic stem cells in the bone marrow, where they pass through 
several developmental stages and rearrangements of their heavy chain and light chain 
genes. When they reach the immature stage, B cells are ready to exit the bone marrow and 
complete their development to the mature stage. The genes encoding immunoglobulins 
(Igs) are assembled from segments in a manner entirely analogous to the process for TCR 
genes. Heavy chains are assembled from 4 segments (VH, D, JH and CH) and light chains 
from 3 segments (VL, JL and CL). There are 9 different Ig isotypes (IgM, IgD, IgG1-4, 
IgA1, IgA2 and IgE), and 2 light chain types (κ and λ). Immature B cells expressing IgM 
can interact with antigens. Those immature B cells that are strongly stimulated by antigen 
at this stage either die or are inactivated, thus removing self-reactive B cells. The 
surviving immature B cells migrate to periphery and mature when they express IgD as 
well as IgM. These mature B cells can now be activated if they encounter their specific 
foreign antigen in the peripheral lymphoid organ. 
 
Activated B cells proliferate and differentiate into antibody-secreting plasma cells and 
long-lived memory cells under the direction signals received from T cells and other cells, 
such as dendritic cells. Igs have two purposes; they serve as cell surface receptors for 
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antigen, permitting cell signalling and activation, and second they act as soluble effector 
molecules, which can individually bind to and neutralize antigens. B cells can change 
from the production of IgM and IgD to other isotypes, such as IgG, IgA and IgE, a process 
called class-switching. In class-swithing, a DNA sequence between VDJ unit and the 
genes encoding IgM and IgD is cut and ligated to a similar sequence in front of another Ig 
C-region gene encoding any of the subclasses of IgG, IgA or IgE. This process is partly 
under the control of cytokine production (Bonilla and Oettgen, 2010; Schroeder and 
Cavacini, 2010). 
 
IgM is the first Ig expressed during B cell development. IgM functions by opsonizing 
antigen for destruction and fixing complement. Circulating IgD is found at very low levels 
in the serum and its function is still unclear. The membrane bound form of IgD is 
expressed on the membranes of B cells when they leave the bone marrow and migrate to 
secondary lymhoid organs. IgG is the predominant isotype found in the body. Four IgG 
subclasses have been identified: IgG1, IgG2, IgG3 and IgG4 in human and IgG1, IgG2a, 
IgG2b and IgG3 in mouse. IgG efficiently opsonizes pathogens for engulfment by 
phagocytes and activates the complement system. IgA is a less potent opsonin and is the 
principal Ig detected in secretions. IgA operates mainly in epithelial surfaces, where 
complement and phagocytes are not normally present.  IL-4 and IL-13 promote switching 
to IgE. IgE is present only at very low levels in the blood or extracellular fluids, but is 
bound to high-affinity receptors on mast cells and basophils (Schroeder and Cavacini, 
2010). 
5.1.3 Cytokines 
Cytokines are small proteins (8-30 kD) that are secreted by various cells in the body. They 
can be divided according to cell subset from which they are secreted or by their chemical 
structure. Cytokines are usually released in response to activating stimulus and mediate 
inflammatory reactions through their specific receptors. One group of cytokines are 
interleukins, which are secreted by leukocytes and which are responsible for the 
communication among different leukocytes. The first interleukin, interleukin-1 (IL-1) was 
discovered in 1977 and the number of interleukins is continuously growing. To date more 
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than 40 cytokines have been designated as ILs. ILs are divided into their distinct family 
according to their sequence homology and receptor chain similarities or according to their 
functional properties (Akdis et al., 2011).  
 
Proinflammatory cytokines IL-1α, IL-1β, IL-6 and TNFα are mainly produced during the 
early stage of inflammatory reaction. Depending on the outcome of the inflammatory 
response and the cytokine-producing cell type, IL-12 and IL-18 can act either as 
proinflammatory or Th1 type cytokines. IL-1 and IL-18 belong to the same cytokine 
family and share structural similarities. However, the biological activity of IL-18 is more 
reminiscent of IL-12 than IL-1. IL-12 and IL-18 are potent inducers of IFNγ. The IL-18 
receptor is upregulated by IL-12 and thereby these two cytokines act in a synergistic 
manner to stimulate IFNγ. IL-12 is mainly derived from DCs, whereas IL-18 is expressed 
by a range of cells (Borish and Steinke, 2003). IL-1 is primarily produced by mononuclear 
phagocytic cells but is also synthesized by endothelial cells, keratinocytes and neutrophils. 
IL-1 has diverse potentiating effects on cell proliferation, differentiation, and on the 
function of many innate and specific immune cells. IL-1 activates T cells by enhancing the 
production of IL-2 and promoting the IL-2 receptor. Other cytokines which belong to the 
IL-1 family in additon to IL-1α and IL-1β are IL-18 and IL-33. IL-6 is part of the cytokine 
family that uses the common signal transducing component gp130 (CD130). Other 
members of this IL-6-like family are IL-11, IL-27 and IL-31 (Commins et al., 2010). IL-6 
is mainly produced by mononuclear cells similarly to IL-1, however it can also be 
synthesized by T and B cells, fibroblasts, endothelial cells and keratinocytes. IL-6 share 
many activities with IL-1, but is also involved in the differentiation of B cells into Ig-
secreting mature plasma cells. 
 
The TNF superfamily consists of e.g. TNFα, TNFβ, B cell activation factor (BAFF) and 
proliferation-inducing ligand (APRIL). TNFα mainly originates from mononuclear 
phagocytes, whereas TNFβ is primarily lymphocyte-derived (Beutler and Cerami, 1989). 
TNFα is also produced by neutrophils, lymphocytes, NK, endothelial cells and mast cells. 
TNFs can have direct cytotoxic effects on cancerous cells and they also interact with 
endothelial cells to help the egress of inflammatory cells to the site of inflammation: 
Specifically TNFα induces the intercellular adhesion molecule (ICAM) 1, vascular cell 
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adhesion molecule (VCAM) 1 and E-selectin. BAFF and APRIL are expressed in bone 
marrow nonlymphoid cells and in developing B cells. 
 
There is also a group of anti-inflammatory cytokines, including IL-1 receptor antagonist 
(IL-1ra), TGFβ and IL-10. IL-10 is primarily produced by regulatory T cells, monocytes 
and B cells (Del Prete et al., 1993). IL-10 can evoke downregulation of MHCII in APCs 
(Akdis and Akdis, 2009a) and it also inhibits the production of many proinflammatory 
cytokines and chemokines (de Waal Malefyt et al., 1991), and mediates allergen tolerance 
in allergen-specific immunotherapy (Akdis and Akdis, 2009b). TGFβ is produced by 
various cell types, including eosinophils, monocytes and regulatory T cells. It has a largely 
inhibitory effect on B cells and T cells e.g. it induces apoptosis and inhibits proliferation. 
In contrast to the anti-inflammatory influences TGFβ is central in the differentiation of 
Th17 and Th9 cells (Commins et al., 2010). 
 
CD4
+
 Th cells are divided into distinct subsets according to their cytokine profile, such as 
Th1, Th2, Th9, Th17, Th22 and T-follicular effector cells. Th1 cells, cytotoxic CD8
+
 T 
cells and B cells produce IFNγ. In addition, cells of the innate immunity (eg, NK cells, 
NKT cells and macrophages) can produce IFNγ. IFNγ is essential in the development of 
Th1 response and the isotype class-switching to IgG2a. High levels of IFNγ activate 
macrophages to kill microbes, promote cytotoxic activity of other cells and induce 
apoptosis of epithelial cells in the skin and mucosa. In addition, IFNγ increases the 
expresson of MHCI and MHCII molecules on APCs (Akdis et al., 2011). 
 
Th2 cells produce IL-4, IL-5, IL-9 and IL-13. These cytokines are crucial in the 
production of allergen specific IgE and play an important role in eosinophilia and mucus 
production. Th2 cytokines also mediate immune responses against helminth infections. 
Th2 cytokines are produced by Th2 cells, basophils, mast cells and eosinophils (Akdis et 
al., 2011). IL-4 is the major Th2 cytokine, which induces Th2 cell development. It also 
suppresses Th1 cell development and induces IgE class switching in B cells. Support for 
the major role of IL-4 as an inducer of Th2 development has been obtained by 
experiments conducted in IL-4 and IL-4Rα deficient mice: These animals suffer from 
defects in Th2 cell differentiation and have reduced serum concentrations of IgG1 and IgE 
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(Kuhn et al., 1991). IL-5 was originally described as an eosinophil and B cell growth 
factor (Milburn et al., 1993). IL-5 essential in eosinophil survival, activation, 
differentiation and adhesion (Lopez et al., 1988; Yamaguchi et al., 1988) and it is mainly 
produced by Th2 cells, eosinophils and mast cells (Akdis et al., 2011). It has been reported 
that IL-5 deficient mice are protected from eosinophilia, airway hyperreactivity to inhaled 
methacholine and lung damage (Foster et al., 1996). IL-13 was first described in 1989. 
This cytokine activates the same signal transduction pathway as IL-4 and also induces IgE 
production. It is produced by Th2 cells, basophils, eosinophils and NKT cells (Brown et 
al., 1989). T cells from IL-13 deficient mice produce less IL-4, IL-5 and IL-10 compared 
with wild-type (WT) T cells. Moreover, IL-13 deficient mice exhibit lower basal levels of 
serum IgE (McKenzie et al., 1998). Other Th2 cell-derived cytokines are IL-9, IL-25 and 
IL-31. 
5.1.3.1 Epithelial-derived, Th2- inducing cytokine IL-33 
IL-33 is a newly described cytokine which belongs to the IL-1 family. It acts as an inducer 
of Th2 type responses and is derived from cells of barrier tissues, including skin, lung, and 
gut. Many cell types, skin keratinocytes, endothelial cells, fibroblasts, smooth muscle cells 
and macrophages are known to produce IL-33, which is released by necrotic cells. IL-33 
binds to ST2-expressing cells, including Th2 cells, mast cells, eosinophils, macrophages, 
and DCs to produce proinflammatory or Th2 type cytokines, especially IL-5 and IL-13 
(Liew et al., 2010; Schmitz et al., 2005) (Fig 2.). However, IL-33 is not produced by Th2 
cells, and its signalling pathway is distinct from the classical Th2 cytokines. IL-33 signals 
through the membrane bound IL-33 specific receptor ST2 (also known as IL-1RL1, T1, 
DER4 and Fit-1) and the IL-1 receptor accessory protein IL-1RAcP, which serves as a 
shared co-receptor. Binding of IL-33 to its receptor complex recruits the adaptor molecule 
MyD88 and IL-1R-associated kinase IRAK. Activated receptor complex induces 
activation of signalling proteins, including transcription factor and the mitogen-activated 
protein kinase pathway. These two pathways (MAPK-dependent and NF-κB-dependent) 
may act synergistically or on their own to induce the gene expression of proinflammatory 
cytokines, e.g. IL-1β, IL-6 and TNFα or Th2 cytokines IL-5 and IL-13 (Liew et al., 2010). 
In addition to its cytokine function, IL-33 can act as a nuclear factor and interact with the 
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transcription factor NF-κB, and therefore it might also be able to dampen the 
inflammatory response (Ali et al., 2011). However, biological effects of nuclear IL-33 are 
unclear at present. 
 
 
 
 
 
 
 
 
 
     
 
  
 
 
 
 
 
 
 
 
   
 
Figure 2 IL-33-producing cells and ST2-expressing cell types. IL-33 binds to the receptor 
complex ST2/IL-1RAcP and promotes the production of Th2 cytokines. Soluble 
ST2(sST2) can bind IL-33, thus preventing the binding of IL-33 to its 
receptor.External and internal signals i.e. scratching, allergen, superantigen, virus or 
filaggrin mutation can induce IL-33 expression in keratinocytes.EC endothelial cell, 
KC keratinocyte, MΦ macrophage, MC mast cell, Eos eosinophil DC dendritic cell, 
Th2 T helper 2. 
Th2
Eos
KC
DC
TNFα+ 
IFNγ
scratching
allergen
virus
superantigen
flg mutation 
sST2
IL-33
ST2
Th2 response
fibroblast
MC
MФ
EC
  
 
 
26 
5.1.4 Chemokines 
Chemokines are a group of small (8-12 kD) cytokines which possess the ability to induce 
cell migration or chemotaxis. Generally, interleukins and chemokines co-operate in 
inflammatory reactions. Chemokine activity is regulated through binding to the 7-
transmembrane, G protein-coupled receptor superfamily. Traditionally, chemokines and 
their receptors are divided into four families (CXC, CC, C and CX3C) on the basis of the 
pattern of cysteine residues in the ligands; C representing cysteine and X/X3 representing 
one or three noncysteine amino acids. At present, more than 50 chemokines and 20 
chemokine receptors have been described. Many of the chemokine receptors can bind to 
more than one ligand. Chemokines can also be classified according to their functional 
properties. Inflammatory chemokines are expressed by circulating leukocytes or other 
inflammatory cells upon activation, whereas homeostatic chemokines are constitutively 
expressed (Allen et al., 2007). The expression of inducible chemokines is often triggered 
by the inflammatory cytokines, such as TNF, IFNγ, microbial products or trauma. By 
acting together, chemokines and other cytokines regulate both innate and adaptive 
immunity in responses to infection, tissue damage and other physiological abnormalities. 
Although chemotaxis is the main feature of chemokines, they also regulate T cell 
development and the trafficking of APCs to the lymphoid organ. Chemokine receptor 
CCR7 expression on the surface of DCs allows these cells to accumulate in the draining 
LNs and T cell areas of the LN (Mackay, 2001).  
 
The CC-chemokine family has been studied in Th2-associated allergic diseases. Th2 cells 
express CCR4, CCR8 and CCR10. The ligands for CCR4 are CCL17 and CCL22. CCL1 
and CCL8 are known ligands for CCR8, which has been shown to be critical in Th2 cell 
homing into allergen-sensitized skin in a mouse model of AD (Islam et al., 2011). Also 
another chemokine receptor plays an important role in skin-homing of Th2 cells. Skin-
derived chemokine, CCL27, is expressed in keratinocytes and attracts CCR10-expressing 
Th2 cells to the site of inflammation (Homey et al., 2002). In addition, CCL11, CCL24 
and CCL26 attract eosinophils through the chemokine receptor CCR3. The CXC-
chemokine family members, CXCL9, CXCL10 and CXCL11 are IFNγ-inducible 
chemokines which are involved in the recruitment of CXCR3-expressing Th1 cells. 
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5.2 Allergy 
The adaptive immune response is a crucial component of host defence against infection 
and it is essential for normal health. Adaptive immune responses are sometimes elicited by 
antigens not associated with infectious agents, and they can provoke an inflammatory 
disease. In some genetically susceptible individuals, exposure to an antigen disrupts the 
natural tolerance, leading to sensitization i.e. an allergic (IgE) immune response to the 
antigen (called allergen). When sensitized subjects are exposed to allergens clinical 
(allergic) symptoms may occur. The term allergy was introduced in 1906 by Viennese 
pediatrician Clemens von Pirquet and it comes from the Greek word allos, meaning 
changed or altered state, and the word ergon, meaning reaction or reactivity. Allergies are 
hypersensitivity reactions to specific substances called allergens, such as pollen, insects, 
drugs or food. 
 
Hypersensitivity reactions can be classified into four broad types. Type I hypersensitivity 
reactions are immediate-type allergic reactions mediated by IgE, whereas type II and type 
III hypersensitivity reactions are mediated by IgG and complement. Type IV 
hypersensitivity reactions are mediated by T cells i.e. Th1, Th2 or cytotoxic T cells. 
Allergic diseases are largely driven by IgE-dependent mechanisms, but many of the 
allergic diseases exhibit chronic features characteristic of Th2 cell-mediated type IV 
hypersensitivity (Murphy, 2012). 
 
The major allergic diseases include allergic rhinitis, allergic asthma, food allergies, 
urticaria, anaphylaxis and atopic dermatitis. The term allergic (or atopic) implies not only 
that the patient has become sensitized but also that an allergen is the reason for the 
sensitization and clinical symptom. Allergen-specific immune responses are the results of 
host adaptive immunity maintained by T and B cells. The inflammatory reactions 
encountered in the different allergic diseases, including allergic asthma, allergic rhinitis 
and atopic dermatitis share several characteristics. In these diseases, IgE-dependent 
activation of tissue mast cells and infiltration of eosinophils and activated CD4
+
 Th2 cells 
are characteristic features of the disease. Other inflammatory cells may also participate in 
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allergic inflammation, e.g. basophils, dendritic cells, and in the more severe forms of the 
disease, also neutrophils and CD8
+
 T cells may be involved (Barnes, 2011). 
 
Many features of allergic inflammation are similar to those encountered in the type of 
inflammation that result from immune responses to helminths and parasites. The main 
biological role of IgE is thought to be participation in adaptive immunity to parasitic 
worms, which are prevalent in the less developed countries. In industrialized countries, 
IgE-mediated allergic responses to environmental antigens predominate and are an 
important cause of disease. Today, almost half of the population in Europe and North 
America has become sensitized to one or more common environmental antigens (Murphy, 
2012). In addition, genetic factors have an important influence on whether atopy develops, 
and several genes have been identified to be associated with asthma and other allergic 
diseases. 
5.2.1 IgE and IgE-mediated allergic reactions 
 
The discovery of IgE occurred much later than the discovery of the other Ig subclasses. 
Praunitz and Kustner discovered a transferable tissue-sensing factor in the serum in 1921. 
This was the first clue to the existence of hypersensitivity reactions. Four decades later, in 
1967, this factor was identified as an Ig subclass IgE by Gunnar Johansson in Sweden and 
Kimishige and Teruko Ishizaka in the United States (Holgate, 1999). IgE is produced both 
by plasma cells in LNs draining the site of antigen exposure and by plasma cells at the site 
of allergic reactions, typically in mucosal tissue or the skin. 
 
Type I hypersensitivity reactions are allergic reactions attributable to the production of IgE 
against external antigens. IgE is mainly localized in tissues where it is, through high-
affinity receptors (FcεRI), tightly bound to the surface of mast cells, basophils, antigen-
presenting cells. Binding of antigen to IgE cross-links these receptors, triggering the 
release of mast cell mediators such as histamine, lipid mediators and cytokines. Low-
affinity receptors for IgE (FcεRII, known also as CD23) are expressed on B cells, 
monocytes and DCs (Murphy, 2012). 
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The IgE-mediated activation of mast cells orchestrates an inflammatory cascade that is 
amplified by the recruitment of several cell types including eosinophils, Th2 cells, 
basophils and B cells. The physiological importance of this reaction is a defence against 
parasite infection. However, in an allergic reaction, acute and chronic inflammatory 
reactions triggered by mast cells evoke many important pathophysiological consequences, 
such as increasing vascular permeability, contracting smooth muscle, amplifying Th2 
response, promoting the eosinophil maturation and activation, stimulating mucus 
production and attracting eosinophils, basophils and Th2 cells. These biological effects 
depend on the molecules being secreted by the mast cells. In allergic inflammation, also 
structural cells at the site of allergen exposure, such epithelial cells, fibroblasts, vascular 
cells and airway smooth muscle cells are important sources of inflammatory mediators 
(Barnes, 2011; Galli and Tsai, 2012; Murphy, 2012). 
 
The allergic inflammation can be divided into early events, called early phase reactions, 
which are mediated by short-lived agents such as histamine. Late phase reactions involve 
leukotrienes, cytokines, chemokines and the recruitment and activation of eosinophils, 
basophils and antigen specific T cells. Early-phase reactions are induced within seconds to 
minutes of the allergen challenge, whereas late-phase reactions occur after several hours 
(Barnes, 2011; Galli et al., 2008b). 
 
The early-phase reactions (type I hypersensitivity reactions) occurring within minutes of 
allergen exposure are mediated by transmitters secreted by tissue mast cells. In sensitized 
individuals, these mast cells already have allergen-specific IgE bound to their surface 
FcεRI. Mast cell degranulation begins within seconds of antigen binding, releasing an 
array of preformed and newly generated inflammatory mediators. The secretions of 
preformed mediators occur when the membrane of the cytoplasmic granules fuses with the 
plasma membrane of the mast cell in a process called degranulation. This exocytosis 
process releases the granule contents to the external environment. The compounds 
released include histamine, proteoglycans (heparin), proteases (tryptase), enzymes, growth 
factors, and cytokines (Galli et al., 2008a). The signs and symptoms of early phase 
reactions vary according to the site of the reaction and can include vasodilation, increased 
vascular permeability, constriction of bronchial smooth muscle and increased secretion of 
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mucus. Basophils can also mediate these early phase reaction since they also express the 
FcεRI. 
 
The late-phase reaction occurs between 3 and 9 hours after antigen challenge and is 
attributable to the continued synthesis and release of inflammatory mediators, which are 
more slowly than the preformed mediators by mast cells. These newly synthesized 
mediators are cytokines, chemokines and growth factors. Late phase reactions are 
coordinated in part by certain long-term effects of the mediators released by activated 
mast cells during early phase reactions and in part by antigen specific T cells. Late-phase 
reactions do not develop in all sensitized individuals and in some patients there may be no 
clear clinical separation between the end of the early phase and the onset of the late phase 
(Galli et al., 2008b). In the skin, Th2 type cells, and later also Th1 type cells, granulocytes 
(eosinophils, neutrophils and basophils) and monocytes become recruited during late-
phase reactions. While mast cells account for the early response to allergens in the skin 
and airways, it is not clear how important they are for the development of late phase 
responses and for the chronic allergic inflammation (Barnes, 2011). 
 
When the allergen exposure is continuous or repetitive, inflammation persists and cells of 
innate and adaptive immunity can be found in the tissues at the site of allergen challenge. 
A long-term allergen exposure can cause a chronic allergic inflammation, which is mostly 
a Th2 type IV hypersensitivity reaction (Galli et al., 2008b). These chronic reactions can 
be responsible for serious long-term diseases, such as chronic asthma and AD (eczema).  
 
The term, protein contact dermatitis (PCD), was first reported 1976 (Hjorth and Roed-
Petersen, 1976). PCD is caused by food proteins and natural rubber latex protein in food 
handlers and health care workers. The most frequent symptoms are chronic or recurrent 
eczema of the hands and forearms. Although the exact pathophysiological mechanism of 
PCD is not fully understood, the pathogenesis of PCD is considered to involve a 
combination of allergen-specific IgE-mediated type I hypersensitivity and delayed type IV 
allergic reactions (Janssens et al., 1995; Levin and Warshaw, 2008). 
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Th2 cells are important in orchestrating allergic inflammation. Th2 cells are recruited and 
activated at the sites of allergic inflammation and produce many cytokines e.g. IL-4, IL-5 
IL-9 and IL-13. This complex cytokine network is the foundation for the initiation of Th2 
type immune responses. Epithelial-derived cytokines TSLP, IL-25 and IL-33 are believed 
to be important for Th2-mediated allergic inflammation (Kinoshita et al., 2009; Smith, 
2010). Eosinophils are also present in allergen exposed tissue and circulation. They are 
granylocytic leukocytes that originate in bone marrow. When Th2 cells are activated and 
IL-5 produced, eosinophils are increased in the bone marrow and they are released into the 
circulation. From the circulation, CC chemokines, called eotaxins (CCL11, CCL24 and 
CCL26) attract eosinophils through the CCR3 chemokine receptor to the inflammatory 
site. Th2 cells can also express CCR3 and migrate toward eotaxins. Like eosinophils, also 
FcεRI-expressing basophils are recruited to the site of IgE-mediated allergic reactions. 
IgE-mediated allergen activation or cytokine activation leads to the release of histamine 
from basophilic granules. In addition, basophils can produce IL-4 and IL-13 (Barnes, 
2011; Galli et al., 2008b; Murphy, 2012). 
5.3 Atopic diseases 
A genetic predisposition to become IgE-sensitized to an environmental allergen is called 
atopy. Not all contacts with an allergen will lead to sensitization, and not all sensitizations 
will lead to a symptomatic allergic reaction. In addition to genetic factors, also 
environmental factors contribute to the tendency to become atopic. The skin is one of the 
largest organs affected by both external and internal factors. Many skin diseases including 
AD, contact dermatitis, urticaria and psoriasis are mediated by immunological responses 
originating from abnormalities in innate and adaptive immunity. 
 
AD is a complex disease characterized by dry and itchy skin, a cutaneous barrier defect, 
enhanced allergen priming, susceptibility to cutaneous bacterial colonization and infection 
and cutaneous inflammation driven by Th2 cells. In addition, it is often associated with 
FLG deficiency. 
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5.3.1 Atopic dermatitis 
5.3.1.1 Prevalence 
AD (atopic eczema) is one of the most common chronic inflammatory skin diseases with 
prevalence rates up to 20 % in children and 3 % in adults. High prevalence rates have been 
observed in a number of developing and already developed countries: over a million of 
children in 97 countries suffer from AD (Odhiambo et al., 2009; Williams et al., 2008). 
The prevalence varies extensively between countries from less than 2 % in Iran and China 
to around 20 % in Australia, England and Scandinavia. In children, the onset of AD occurs 
in 45 % of cases during the first 6 months of life, 60 % during the first year with 85 % 
being affected before the age of 5. Eczematous lesions often start during early infancy and 
childhood, but can also persist into or even start in adulthood (Leung and Bieber, 2003). 
5.3.1.2 Genetics 
AD is a highly heritable disease. The increased incidence of AD in children is associated 
with the prevalence of atopic disease in their parents; a positive parental history is the 
strongest risk factor for AD, with the incidence rate being doubled if AD is present in one 
parent, and tripled if both parents are affected (Bieber, 2010). In a large cohort study, the 
risk of a child having AD if one or both parents had AD was higher compared with the 
risk if one or both parents had asthma or allergic rhinitis (Dold et al., 1992). Mutations in 
the FLG gene are known to be a major risk factor for AD (Palmer et al., 2006) as well as 
for other atopic diseases. Furthermore, AD exhibits strong genetic linkage to chromosome 
1q21, which contains genes encoding FLG and other  keratinocyte structural proteins 
(Irvine et al., 2011). FLG is known to play an important role in skin hydration and it is 
essential for skin barrier function. However, FLG expression is reduced also in patients 
with AD who do not carry FLG mutations (Howell et al., 2007). It has been also 
demonstrated that Th2 type cytokines are able to downregulate FLG expresson (Howell et 
al., 2007). The epidermal differentiation complex contains several other families of genes 
encoding loricrin, involucrin and hornerin (Irvine et al., 2011). Since only one third of AD 
patients have been identified as FLG mutation carriers, also other genetic and 
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environmental co-factors are believed to act on skin barrier function. Genome-wide 
association studies (GWAS) have been used in an attempt to identify genes associated 
with AD with linkage being detected on chromosomes 1, 3, 4, 5, 11, 13, 15, 17, 18, 19 and 
20 (Barnes, 2010; Boguniewicz and Leung, 2011).  
 
Although more than 100 studies have reported an association of AD and a candidate gene, 
most of these were trials insufficiently powered, and suffered from heterogeneity in the 
AD phenotype making replication difficult. From these published studies, there are reports 
of 81 genes, of which 46 genes had at least one positive association study reported. Only 
13 genes (FLG, IL-4, IL-4RA, SPINK5 (serine protease inhibitor Kazal-type 5), CMA1 
(mast cell chymase), IL-13, RANTES, CD14, DEFB1 (defensin beta 1), GSTP1 
(glutathione S-transferase P1), IL-18, NOD1 (nucleotide-binding oligomerization domein 
1) and TIM1 (T cell immunoglobulin domein 1) of these 46 genes have been positively 
associated in two or more independent studies. Thus, FLG has been detected in the highest 
number of studies. Two major network groups were identified in the evaluation of these 
81 genes (Barnes, 2010). Genes involved in antigen presentation, cell-mediated and 
humoral immune responses, including CD14, GATA3, IL-4, IL-18, NOD1 and TLR2 are 
associated with AD. The other genes are BCL2A (B cell lymphoma gene 2a), BDNF 
(brain-derived neurotrophic factor), RANTES, CSF2 (colony-stimulating factor 2), 
GSTP1, IL5, IL12B (IL-12p40), IL12RB1 and SOCS3 (suppressor of cytokine signalling 
3), which are involved in cell signalling, cellular movement as well as in hematologic 
system development and function (Boguniewicz and Leung, 2011). 
 
GWAS have also revealed an association of a common variant on chromosome 11q13 
(Esparza-Gordillo et al., 2010). This same risk allele has been reported to be associated 
with Crohn's disease (Ellinghaus et al., 2012), suggesting that this genetic modification 
might be involved in epithelial inflammation and barrier dysfunction in general 
(Marenholz et al., 2011; O'Regan et al., 2010). Furthermore, one recent GWAS identified 
two new risk loci for AD in chromosome 11 (upstream of OVOL1, transcription factor 
OVO homologue-like 1), and in chromosome 19 (near ACTL9, actin like protein 9), 
which are near to genes known to have roles in epidermal proliferation and differentiation, 
thus suppporting the importance of abnormalities in skin barrier function in the 
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pathogenesis of AD. They also observed an association signal within the cytokine cluster 
5q31.1, which seemed to be composed of two distinct signals, one at IL13-RAD-50 (IL13-
DNA repair protein RAD-50) and the other at IL-4-KIF3A, (IL4-kinesin family member 
3A) (Paternoster et al., 2012). However, functional analyses will be needed to clarify the 
exact relevance of these genetic modifications in AD. 
5.3.1.3 External triggering factors 
Most of the AD patients have elevated concentrations of total and allergen specific IgE in 
their circulation, emphasizing the possible contribution of allergens in AD. High serum 
IgE levels correlate with the severity of AD. Moreover, the severity of AD is also 
positively correlated with the number of positive skin prick test responses and IgE levels 
(Flohr et al., 2004). The epidermis is not only a primary defence but also a sensor to the 
external environment. Defects in the skin barrier promote unobstructed entry to pathogens, 
allergens and other molecules. Stress, bacterial or viral infections, the exposure to 
aeroallergens or food allergens can aggravate or trigger the symptoms of AD (Bieber, 
2010; Boguniewicz and Leung, 2011; Novak and Leung, 2011; Wollenberg et al., 2011). 
 
Food allergens are important triggers of AD in children. Eczematous skin lesions can 
appear after ingestion of food as well as epicutaneous food application. AD and food 
allergy commonly co-exist, particularly in those individuals with early onset, severe and 
persistent AD. Approximately 40 % of children with AD have a food allergy (Sicherer and 
Sampson, 1999). In a mouse model, orally immunized mice antigen specific gut homing T 
cells could be reprogrammed to express skin-homing molecules. These T cells were then 
recruited into the skin in response to contact with food allergens placed on the skin 
(Oyoshi et al., 2011). This may well explain the flare-up of lesions following cutaneous 
contact with a food allergen in orally sensitized AD patients. 
 
Aeroallergen such as house dust-mite, animal dander, moulds and pollen can aggravate 
skin lesions through either inhalation or skin contact. Several groups have demonstrated 
that eczematous skin lesions can be induced by aeroallergens. Patch testing of 
aeroallergens in patients with AD was first reported in 1982 by Mitchell et al.(Mitchell et 
al., 1982). The house dust mites (HDMs) Dermatophagoides pteronyssinus (Der p) and 
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Dermatophagoides farinae (Der f) are major allergens in HDM-sensitized AD patients. 
HDM allergens possess high enzymatic activity which facititates their penetration through 
the impaired epidermal barrier in patients with AD. HDM allergens may act as irritants 
when they are in contact with AD skin, since some of those are serine and cysteine 
proteinases, which can activate proteinase-activated receptors (PARs). PAR-2 is expressed 
in the skin and respiratory epithelium and is believed to be involved in HDM allergy (Cho 
et al., 2012; Jacquet, 2011). 
 
An impaired skin barrier can also increase the susceptibility to the bacterial colonization 
by pathogenic bacteria. Lesional and nonlesional skin of patients with AD is highly 
colonized with Staphylococcus aureus and many (31-65 %) patients with AD are 
colonized with superantigen producing strains of S. aureus. In addition, other molecules 
released by S. aureus can contribute to the pathogenesis of AD. S. aureus can release 
fibronectin-binding protein (FBP), which has been demonstrated to be IgE-reactive 
requiring antigen presentation (Reginald et al., 2011). S. aureus colonization may be 
traced to a reduced production of AMPs in AD skin, or reduced S. epidermidis 
colonization, which is believed to be a nonpathogenic bacterium which can inhibit the 
growth of S. aureus in the skin (Iwase et al., 2010). The presence of natural moisturizing 
factor (NMF) in the stratum corneum has also been demonstrated to reduce the growth 
rates of S. aureus. In AD skin, the levels of NMF (urocanic acid and pyrrolidone 
carboxylic acid), are reduced partly as a consequence of the FLG mutation and perhaps 
secondarily enhance the growth of S. aureus (Novak and Leung, 2011). 
 
In addition to S. aureus, a skin colonizing yeast, Malassezia sympodialis, often is involved 
in the pathogenesis of the disease. Malassezia sympodialis can produce, express and 
release allergens to a greater extent when cultured at higher pH, thus its growth is 
favoured in the high pH of the skin of patients with AD (Selander et al., 2006). In a 
subgroup of AD patients, hyperreactivity to human protein is regarded as a trigger factor. 
Such autoreactivity to human proteins has been described for a repertoire of IgE-binding 
autoantigens that cross-react with environmental antigens, including fungal antigens. 
Recently, it was demonstrated that T cells of patients with AD could cross-react with 
thioredoxin derived from a lipophilic yeast, Malassezia sympodialis and human 
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thioredoxin. These T cells were CD4
+
, expressed cutaneous lymphocyte antigen (CLA) 
and secreted Th1, Th2, Th17 and Th22 cytokines (Balaji et al., 2011). 
 
In patients with AD, a genetic predisposition for skin barrier dysfunction and defects in 
innate and adaptive immune responses can lead to a higher frequency of bacterial and viral 
infections. Herpes simplex and Molluscum contagiosum are the most common virus 
infections in patients with AD (Wollenberg et al., 2011). Th2 responses in atopic 
dermatitis can lead indirectly to exacerbation of the condition by making the individual 
more susceptible to certain infections. It was recently demonstrated that the STAT6 gene 
could increase viral replication in the skin of patients with a history of eczema herpeticum 
(Howell et al., 2011). 
5.3.1.3.1 Staphylococcal enterotoxins 
Staphylococcal and streptococcal enterotoxins are a family of toxic proteins secreted by S. 
aureus and Streptococcus pyogenes. More than 20 different enterotoxins are known, with 
SEA and SEB being the best characterized. They are also regarded as superantigens as 
they act as potent T cell activators, i.e. they bind directly to MHCII on APC and are 
recognized by T cells without being processed into peptides by APCs normally required 
for antigen specific immune responses (Fig. 3). Staphylococcal enterotoxins cause food 
poisoning and toxic shock syndrome, but they can also modify the inflammatory reaction 
in AD. However, the role of viral superantigens in human disease is less clear. 
Staphylococcal enterotoxins produced by S. aureus (SEA, SEB, SEC, SED, SEE, SEG, 
SEH, SEI and SEJ) can aggravate the skin inflammation in AD by binding to MHCII and 
TCR ultimately leading to increased T cell stimulation by activating up to 20 % of T cells, 
whereas a typical conventional antigen activates less than 0.01 % of T cells (Sundberg et 
al., 2002). Moreover, previous research has demonstrated that a third receptor, the 
principal costimulatory molecule, CD28, might be also involved in binding of SEB (Arad 
et al., 2011). 
Bacteral superantigens elevate the number of T cells and increase the expression of Th2 
and Th1 type cytokines in AD skin, thus aggravating the skin inflammation. Superantigens 
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also have antigenic properties and superantigen-specific IgE mediates inflammatory 
reactions in AD skin. Therefore superantigens binding to IgE coupled to FcεRI on cell 
surface can activate FcεRI-bearing mast cells, basophils and DCs, which all play 
important roles in atopic skin inflammation (Fig 3). Moreover, the levels of specific IgE 
antibodies directed against staphylococcal superantigens correlate with the skin disease 
severity (Leung et al., 1993). 
 
 
 
 
 
 
 
 
 
Figure 3 Binding of conventional antigen and SEB to the MHCII/TCR complex and modulation 
of antigen-induced inflammatory reaction by SEB. 
5.3.1.4 Immunological mechanisms in AD skin 
 
AD patients suffer defects in barrier function and abnormalities in the innate immune 
responses, which can lead to a higher frequency of bacterial or viral infections 
(Wollenberg et al., 2011). The epidermis of AD patients is characterized by significant 
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barrier disruption, partly explained by loss-of-function mutations in the FLG gene, as well 
as the reduced FLG expression due to overexpression of Th2 type cytokines in the skin 
(Howell et al., 2007). Early events initiating atopic skin inflammation involve 
abnormalities in skin barrier function and mechanical trauma induced by scratching or 
irritation leading to increased susceptibility to allergic sensitization and microbial 
colonization (Boguniewicz and Leung, 2011). This results in the upregulation of 
proinflammatory cytokines and the production of so called pro-Th2 cytokines, including 
IL-33, TSLP and IL-25. These are barrier secreted cytokines which are known to trigger or 
amplify Th2 type response in the skin. In human and mouse studies, TSLP and IL-33 have 
been produced in the skin as a response to tape stripping (Dickel et al., 2010; Oyoshi et 
al., 2010), which disrupts the skin barrier. TSLP is one of the cytokines produced by 
keratinocytes and it is capable of enhancing the Th2 polarizing properties of DC. 
 
DCs are the most potent APCs in the skin, and these cells express a wide variety of 
receptors on their surfaces. They recognize microbial patterns, damage induced molecules 
and cytokines. When DCs are exposed to an allergen, these cells become reporters of the 
microenvironment and migrate to the draining LNs, where they activate naïve T cells. 
Circulating T cells which infiltrate into the skin express the cutaneous lymphocyte antigen 
(CLA), and many of these cells display a Th2 phenotype. These Th2 cells bind to E-
selectin, an adhesion molecule expressed by endothelial cells in inflamed tissue, and 
respond to the chemotactic gradients established by cytokines and chemokines. There is a 
crosstalk between endothelial cells and T cells in acute AD. In addition, other cutaneous 
cells, including mast cells and macrophages, interact with endothelial cells. 
 
Although CD4
+
 cells predominate over CD8
+
 cells in AD skin, there is also evidence that 
CD8
+
 cells can be involved in the pathogenesis of the disease. Th2 type cytokines, 
including IL-4, IL-5 and IL-13, mediate inflammatory reactions in the acute phase of AD. 
In addition to Th2 cells, Th2 type cytokines can originate from mast cells, eosinophils and 
basophils in eczematous skin lesions. During the more chronic phase, Th1 cytokine IFN  
starts to dominate over Th2 cytokines. Recent years have proved that in addition to Th2 
and Th1 dysbalance, skin barrier defects and activation of innate immune pathway are also 
critically involved in the pathogenesis of the disease. The numbers of pDCs which are the 
  
 
 
39 
primary defence cells against viral infections, are reduced in the skin of AD patients. This 
may partly explain why AD patients are more susceptible to viral infections and have 
decreased secretion of type I interferons (Bieber, 2010). Bacteral superantigens elevate the 
number of T cells and increase the expression of Th2 and Th1 type cytokines in AD skin, 
thus aggravating the skin inflammation. Inflammatory cells, including Th2 cell, mast cells 
and DCs representing critical cell subsets in AD, express ST2 receptor (also called T1 or 
IL-1RL1). ST2 is activated by its ligand IL-33, which is known to induce eosinophilia and 
Th2 type cytokines in mice.  
 
In recent years, regulatory T cells have been a focus of interest in allergy research. 
Regulatory T cells are able to suppress T cells through their interactions with effector T 
cells or APCs. In the absence of Foxp3, mice exhibit highly elevated serum IgE levels, 
eosinophilia and increased production of Th2 cytokines (Fyhrquist et al., 2012). It has 
been demonstrated that in vitro Foxp3 T cells lose their suppressive properties after 
stimulation with superantigen (Lin et al., 2011; Ou et al., 2004). 
5.3.1.5 Neuroimmunological factors 
Psychological stress is a well-established trigger and aggravator of AD (Morren et al., 
1994). Skin expresses many of the same neurotransmitters and neuropeptide receptors as 
the central nervous system and it is innervated by cutaneous sensory fibers. 
Corticotrophin-releasing hormone (CRH), serotonin, prolactin and substance P (SP) are 
expressed in the skin, mediating vasodilatation, oedema, itch and pain or sweat gland 
secretion. Dysregulation of these mediators both in the central nervous system and in the 
skin can contribute to the pathophysiology encountered in AD. Neuropeptides released in 
the skin may also mediate neurogenic inflammation, including mast cell degranulation 
(Arndt et al., 2008). Neuropeptides are also present within epidermal nerve fibers, existing 
in close association with epidermal LCs and mast cells, evidence of the intimate link 
between the immune system and the nervous system (Hosoi et al., 1993). 
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5.3.1.6 Treatment 
The current medications for AD are topical corticosteroids as the standard treatment and 
topical calcineurin inhibitors, such as tacrolimus or pimecrolimus as the second-line 
therapy. When topical treatment proves ineffective, phototherapy or systemic therapy with 
antibiotics, immunosuppressives or immunomodulatory agents can be considered. Current 
treatment options have side effects and are occasionally insufficient, thus there is a crucial 
need to develop novel therapies. 
The pathophysiology of AD is complex and regulated by a large number of genetic and 
environmental factors. However, the treatment of AD is mainly limited to symptomatic, 
unspecific anti-inflammatory or immunosuppressive treatment of the flare-ups and the 
disturbed skin barrier. Recently research has focused on the main trigger factors. It has 
become clearer that AD might be the outcome of very heterogenous and different aspects. 
Therefore, it has been proposed that the classification of subgroups of patients with AD 
would shift the treatment strategy toward more individualized, rationale-based therapy 
(Novak and Simon, 2011). 
 
Several pathways could be beneficial in the treatment of AD. Some of them have been 
already evaluated in clinical trials. Oral administration of vitamin D(3)-1,25-
dihydroxyvitamin has been reported to induce the cathelicidin production in the skin of 
patients with AD (Hata et al., 2008) and in cultured human keratinocytes (Schauber et al., 
2008). In addition, therapy with pimecrolimus enhances the expression of cathelicidin 
(Buchau et al., 2008). Therefore, in the subgroup of AD patients which have bacterial or 
viral infections, topical treatment with pimecrolimus and oral administration of vitamin 
D3 would represent a novel approach to compensate for the deficiency of AMPs in the 
skin of patients with AD. 
 
Specific immunotherapy (SIT) has been used for patients with allergic rhinitis or mild 
asthma. For many years, AD has been excluded from the SIT because of side effects and 
unwanted exacerbations of symptoms during the therapy. However, recent studies 
conducted with patients sensitized to HDMs or birch pollen allergens were promising i.e. 
there was a decrease in disease severity and a reduction in the concentrations of allergen 
specific IgE. Patients with AD are most often sensitized with more than one allergen and 
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most likely a combinations of immunomodulatory agents and SIT might be beneficial in 
the future (Bussmann et al., 2006; Darsow et al., 2011). 
 
Pruritus is a key symptom of AD causing sleeplessness and generally impairing the quality 
of life. Treatment of pruritus in AD is difficult and histamine receptor antagonists are of 
only very limited value. The discovery of the link between histamine/histamine receptor 
and IL-31/IL-31 receptor signalling may serve as a novel pathway to develop antipruritic 
therapy (Gutzmer et al., 2009; Kasraie et al., 2010; Novak and Simon, 2011; Sonkoly et 
al., 2006). 
 
A treatment approach to neutralize IgE in AD patients has confirmed that anti-IgE reduced 
the free IgE and the expression of FcεRI on the surface of blood and skin cells in AD. 
Furthermore, the number of DCs and IgE decreased in the skin. However, no significant 
improvement was detected in skin symptoms and pruritus (Heil et al., 2010). The 
depletion of B cells by anti-CD20 resulted in reductions of skin inflammation in all 
studied patients and the effect was sustained over 5 months in five of six patients (Simon 
et al., 2008). The depletion of B cells in the peripheral blood and to a lesser extent in the 
skin was followed by a reduction in the amounts of T cell derived cytokines, including IL-
5 and IL-13 in the skin. In contrast, allergen specific IgE levels were not affected by anti-
CD20 antibody (Simon et al., 2008). 
 
Potential new targets for therapeutic intervention include AMPs, restoration of barrier 
function, antistaphylococcal toxin strategies, Th2 cytokine inhibitors, and modulation of 
pruritus at the neuromediator level. 
5.3.2 The Atopic march 
The first clinical manifestation of atopy is generally considered to be AD: this is the start 
of the atopic march. The atopic march is characterized by the progression of atopic 
dermatitis to asthma and allergic rhinitis later in life. Indeed, more than 50 % of young 
children with severe AD will develop asthma and approximately 75 % will develop 
allergic rhinitis (Spergel, 2010). There is environmental and genetic evidence to suggest 
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that a defect in epithelial barrier integrity may contribute to the onset of AD and the 
progression of the atopic march. 
5.3.3 Allergic asthma 
Asthma is an inflammatory disorder of the airways that have acquired a hyperresponsive 
profile leading to variable airflow obstruction either spontaneously or in response to 
exogenous stimuli. The airway inflammation in asthma is a multicellular process 
involving eosinophils, neutrophils, CD4
+ 
T cells, mast cells and basophils. Allergic 
asthma, in which inflammatory reactions and airway obstruction are triggered by allergen 
exposure in atopic individuals, is the most widely investigated form of asthma. 
 
Asthma is a syndrome characterized by intermittent attacks, breathlessness, wheezing and 
cough. Inflammation in the lungs results in structural changes in the airway including 
epithelial mucus metaplasia, smooth muscle hypertrophy and enhanced subepithelial 
matrix glycoproteins. Childhood asthma is often associated with other allergic disorders.  
At present, 40 % of the Western population is atopic and 7 % of these individuals express 
their atopy in the form of asthma indicating that only some of the atopic patients develop 
asthma and others manifest the atopy in other ways such as rhinitis, food allergies or AD 
(Pearce et al., 1999). Allergic asthma is driven by Th2 cells producing IL-4, IL-5 and IL-
13. In lung tissue, effector T cells augment the survival of eosinophils through the 
secretion of IL-5. Th2-secreted cytokine IL-9 is involved in the recruitment, proliferation 
and differentiation of mast cells, while IL-13 induces airway hyperreactivity, goblet cell 
metaplasia and mucin production. 
 
Activated Th2 cells induce the IgE class-switching in B cells which in turn can activate 
the mast cells, eosinophils and basophils present in the airways. In addition to classical 
DC mediated activation of naïve T cells into Th2 cells, current knowledge supports the 
critical role of airway epithelial derived cytokines in the initiation of the allergic response 
(Locksley, 2010). TSLP mainly acts via DCs, whereas IL-33 and IL-25 are able to directly 
activate ST2-bearing mast cells, basophils and the newly characterized non-T/non-B cells 
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called innate lymphoid cells or nuocytes through their receptors ST2 and IL-25R 
(Locksley, 2010).  
5.4 Experimental models of atopic diseases 
5.4.1 Animal models of AD 
Several mouse models of AD have been developed in attempts to better understand the 
pathophysiology of AD. Those models can be divided into three groups: ezcema induced 
by epicutaneous allergen sensitization, transgenic mice overexpressing or lacking selective 
molecules and mice that spontaneously develop AD-like skin lesions (Jin et al., 2009). 
 
A mouse model of AD induced by repeated epicutaneous ovalbumin (OVA) sensitization 
onto tape-stripped skin was first introduced by Spergel et al. in 1998 (Spergel et al., 1998). 
Epicutaneous OVA-sensitization evokes epidermal and dermal thickening of the skin, 
infiltration of CD4
+
 T cells and eosinophils and increased expression of Th2 cytokines IL-
4, IL-5 and IL-13.  
 
Nc/Nga mice were the first mouse model of AD. These mice spontaneously develop AD-
like lesions when kept under conventional conditions, particularly when the mice are 
infected with mites. However, the disadvantage of this inbred mouse strain is that the 
genetic defect remains unknown. Similar mouse strains are NOA mice, DS-Ng and DS-Nh 
mice which develop spontaneous skin inflammation under conventional conditions(Jin et 
al., 2009). More recently, a 1-bp deletion mutation, analogous to common human FLG 
mutations within the mouse Flg gene, in this spontaneous mouse mutant, flaky tail was 
described. These mice provide new insights into the relationship of human FLG mutations 
and AD pathogenesis (Fallon et al., 2009). 
 
Several genetically modified knockout or transgenic mice have also been used to 
investigate the mechanisms involved in AD. Mice overexpressing a specific cytokine 
including IL-4, IL-31, TSLP and IL-18 have been used as a model for AD. Several 
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knockout mice strains such as RelB and cathepsin E knockout mice have been used as 
tools to investigate the pathogenesis of AD (Jin et al., 2009). Recently it was reported that 
the epidermal ADAM17 (a disintergrin and metalloproteinase domein 17) deficiency 
causes an AD-like inflammation in mice (Murthy et al., 2012). 
5.4.2 Animal models of allergic asthma 
Mice are the most common species being used in animal models of asthma. In the 
majority of studies, mice are intraperitoneally sensitized to allergen with alum as an 
adjuvant and then challenged with the allergen via their airways. In the acute model, mice 
are sensitized for one to nine days, whereas in the more chronic model, the animals are 
sensitized for five to nine weeks (Takeda and Gelfand, 2009). In another asthma model, 
mice are sensitized epicutaneously or intracutaneously without external adjuvant and 
challenged via the airways (Lehto et al., 2005). In both models, mice exhibit airway 
hyperreactivity to inhaled methacholine, local Th2-dominated lung inflammation, tissue 
eosinophilia, mucus hyperproduction and a systemic IgE response. 
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6. AIMS OF THE STUDY 
Although novel insights into the complex pathophysiology of AD have been gained in 
recent years, several of the external triggering factors and the immunological mechanisms 
participating in atopic sensitization and allergic asthma remain undefined. Moreover, there 
is no standardized experimental model with which to investigate new topical therapies in 
AD. 
  
The specific aims of this thesis are: 
 
1. To study whether superantigen can modify the allergen-induced skin inflammation. 
 
2. To investigate the suitability of an experimental AD model to study the efficacies of 
topical drugs. 
 
3. To explore expression profiles and modulation of IL-33 and ST2 in AD. 
 
4. To clarify the functional role of ST2 in the murine model of AD and in an 
experimental model of allergic asthma. 
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7. MATERIALS AND METHODS 
7.1 Mice 
The role of SEB in the murine model of AD (I) was investigated in female Balb/c mice 
obtained from Taconic M&B (Ry, Denmark) and used at the age of 6 weeks. To examine 
the effects of topical drugs in an experimental AD model (II) 6 week old female Balb/c 
mice were obtained from Scanbur A/S (Karlslunde, Denmark). In the IL-33 and ST2 
expression studies with different triggering factors in AD (III) female Balb/c mice from 
Scanbur A/S and filaggrin-deficient (flaky tail ft/ft, ma/ma; double homozygous for the 
flaky tail and matted mutations) mice from Jackson Laboratory (Bar Harbor, ME) were 
used. ST2-/- mice in 129 background (IV) were purchased from EMMA (the European 
Mouse Mutant Archive) and bred and genotyped at the Finnish Institute of Occupational 
Health. WT littermates were used as controls. Animal studies were approved by the State 
Provincial Office of Southern Finland. 
7.2 Patients (III) 
AD patients were identified according to the criteria by Hanifin and Rajka (Hanifin and 
Rajka, 1980). Punch biopsies (6 mm) were taken from either nonlesional or lesional skin 
of 15 patients with chronic AD and from the skin of 13 healthy volunteers. AD patients 
with prick test-confirmed HDM allergy underwent atopy patch tests with HDM. All 
patients had been without topical medication for 1 week and without systemic medication 
for 4 weeks before the skin biopsies were taken. Patient studies were approved by the 
ethics committee of the Hospital District of Helsinki and Uusimaa. 
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7.2.1 Patch tests 
Atopy patch tests were performed with HDM antigen containing a mix of D. farinae and 
D. pteronyssinus species (Chemotechnique Diagnostics, Malmö, Sweden). Skin specimens 
were obtained before and 2, 6, and 48 h after HDM-exposure. In the staphylococcal 
enterotoxin B (SEB) patch tests, SEB (Sigma-Aldrich, St. Louis, MO) at 0.226 µg/µl in 
0.9% NaCl solution was applied in Finn chambers (Epitest, Hyrylä, Finland) on healthy-
appearing dorsal skin of AD patients. Skin specimens were obtained before and at 2, 6, 
and 24 h after SEB-exposure. 
7.3 Cells and stimulations (I, III) 
Mouse skin-draining (axillar) LN cells were collected from AD mice (I) after the 
sensitization. Cell suspensions of pooled (4 mice per group) LN cells were prepared in 
RPMI 1640 medium with Glutamax-I (Invitrogen Life Techologies) supplemented with 5 
% FBS, 1 mM sodium pyruvate, 0.05 mM 2-ME, 100 U/ml penicillin, and 100 µg/ml 
streptomycin. The cells were cultured in the medium at 5 x 10
6
 per ml in 24-well plates in 
the presence of SEB (1 µg/ml) or OVA (50 µg/ml). The cell culture medium was collected 
after 6 hours of culture for protein determination (I). 
 
Primary human dermal fibroblasts (III) isolated from adult skin were purchased from 
Gibco (Paisley, UK) and cultured in Medium 106 according to the manufacturer’s 
instructions (Gibco).  
 
Human immortalized HaCaT keratinocytes (III) were obtained from ATCC (Boras, 
Sweden) and cultured in DMEM (Lonza, Verviers, Belgium) containing 10% FBS, 2mM 
Ultraglutamine1 (Lonza), and antibiotics.  
 
Human primary macrophages (III) were obtained from leukocyte-rich buffy coats from 
healthy blood donors (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland). 
Peripheral blood mononuclear cells (PBMCs) were extracted by density gradient 
centrifugation. Monocytes were differentiated into macrophages by maintenance in 
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macrophage serum-free media supplemented with granulocyte-macrophage colony-
stimulating factor (GM-CSF) in the presence of antibiotics, as described previously 
(Sareneva et al., 1998).  
 
HUVECs (ATCC CRL 1730) were cultured in RPMI 1640 and supplemented with 10 % 
FBS, 2mM Ultraglutamine1 (Lonza) and antibiotics. Cultured cells were stimulated for 2 
and 18 hours (III). 
 
Fibroblasts, HaCaT keratinocytes, macrophages and HUVECs  were stimulated with TNF-
α (20 ng/ml, Biosource International, Camarillo, CA, USA), IL-4 (20 ng/ml, Immuno 
Tools), IFN-γ (500 IU/ml, Immuno Tools, Friesoythe, Germany), with the combination of 
TNF-α and IL-4 and with the combination of TNF-α and IFN-γ for 2, 6 and 18 hours. In 
subsequent studies, human dermal fibroblasts were stimulated with the combination of 
TNF-α and IFN-γ for 18 hours, after which the cells were transfected with a mimetic of 
dsRNA polyinosic-polycytidylic acid [poly(I:C)], 10 mg/ml using Lipofectamine 2000 
transfection reagent (Invitrogen Life Technologies, Karlsruhe, Germany) for 3 and 6 hours 
according to the manufacturer's instructions (III). 
 
Murine mast cells (III) were obtained from bone marrow cells of C57BL/6 mice and 
cultured and identified as previously described (Gombert et al., 2005). Bone marrow cells 
were cultured for 4 wk in 70 % RPMI1640 Glutamax I medium supplemented with 10 % 
FBS, 25 mM Hepes, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.1 mM nonessential 
amino acids (Invitrogen Life Technologies), 25 µM 2-ME (Sigma-Aldrich), and 30 % 
WEHI-3B medium as a source of IL-3. After 2 wk of culture, murine stem cell factor was 
added. The cells were identified as mast cells by May-Grünwald–Giemsa staining and by 
flow cytometric analysis of Kit (>99% of c-kit
+
 cells) and IgE receptor (89% of the cells 
positive) expression. Mast cells were incubated with 10 µg of anti-DNP IgE (Sigma-
Aldrich) in 2 ml of culture medium for 2 h on ice. The plates were centrifuged, the 
supernatant was discarded, and the cells resuspended in 2 ml of medium with 200 ng of 
DNP-human serum albumin (Sigma-Aldrich). The cells were incubated for 6 hours. 
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7.4 Murine models of allergic diseases 
7.4.1 Murine model of AD and sensitization 
The back of the mice was shaved with an electronic razor and tape-stripped by adhesive 
tape to introduce standardized skin injury. Stripping included adhering a piece of tape to 
the shaved skin four times, after which it was removed against the direction of the hair. 
The gauze was secured to the shaved skin with transparent adhesive tape (Tegaderm; 
Owens and Minor) for 1 wk (first sensitization week). Two weeks later (second 
sensitization week), mice were again tape-stripped, and an identical patch was reapplied to 
the same skin site. The last epicutaneous sensitization (third sensitization week) was 
similarly given 2 wk later. Mice were given a total of three 1-wk patch exposures, 
separated from each other by 2-wk intervals, i.e. total duration was 7 wk. One hundred 
micrograms of OVA (grade V; Sigma-Aldrich) in 100 µl of PBS was used for 
epicutaneous sensitization. PBS was used as a control. In experiments I, II and III mice 
were epicutaneously sensitized for 7 weeks (3 sensitization weeks), whereas in experiment 
IV mice were sensitized for 4 weeks (2 sensitization weeks). 
 
In SEB study (I), mice were epicutaneously treated with OVA (OVA group), SEB (SEB 
group), combination of OVA and SEB (OVA/SEB group), or PBS. Two different amounts 
of SEB (Sigma-Aldrich), 0.5 and 5 µg, were topically applied to a 1 x 1-cm patch of 
sterile gauze alone (in 100 µl of PBS) or with OVA (Fig 4). 
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Figure 4 Experimental AD-model with epicutaneous OVA and SEB exposures. Mice were 
tape-stripped and epicutaneously sensitized with OVA, SEB, OVA/SEB and PBS. 
100µg of OVA, and 0.5 µg or 5 µg of SEB was used in a patch. 
 
In the second AD-experiment (II), mice were epicutaneously sensitized with OVA/SEB in 
the first and in the second sensitization weeks. During the third sensitization week, drugs 
were applied to the skin together with the OVA/SEB-mixture in 75% acetone/PBS-
solution. The drug concentrations were as follows: betamethasone-17-valerate (Sigma-
Aldrich) 15 μg/100 μl, tacrolimus (FK-506, Sigma-Aldrich Co) 100 μg/100 μl and 
cipamfylline 100 µg/100 µl. PBS was used as a vehicle during the first and second 
sensitization week and 75% acetone in PBS during the third sensitization/treatment week 
(Fig 5). 
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Figure 5 Experimental AD-model with one-week treatment period with topical drugs. Mice 
were epicutaneously sensitized with OVA/SEB for three weeks. During the third 
sensitization week, corticosteroid, tacrolimus or cipamfylline was included in a patch 
containing OVA/SEB or PBS. 
 
To investigate IL-33 and ST2 expression profiles in AD skin after different triggering 
factors (III), mice were sensitized with OVA and PBS and samples were collected after 
the first and third sensitization weeks. IL-33 and ST2 mRNA expressions were also 
studied after epicutaneous SEB-exposure. SEB was dosed at 0.5 and 5 g /patch. 
Furthermore, IL-33 and ST2 expressions were also studied in OVA/SEB-exposed skin 
after topical betamethasone-17-valerate (15 µg) and tacrolimus (100 µg) treatment. In 
these studies, 2.5 µg of SEB was used together with 100 µg of OVA in a patch. 
 
In subsequent studies the functional role of ST2 was investigated with ST2-/- mice and 
WT littermates (IV). Mice were epicutaneously sensitized with OVA/SEB solution. OVA 
and SEB were dosed at 100 µg and 2.5 μg in a patch, respectively. 
7.4.2 Murine model of allergic asthma (IV) 
To produce allergen induced airway inflammation (IV), epicutaneously sensitized ST2-/- 
and WT mice were rested for one week after the second sensitization week and mice were 
intranasally challenged with 50 µl of PBS (controls) or with 50 µg of OVA diluted in 50 
µl of PBS for three days (Fig 6). 
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Figure 6 Murine model of asthma. ST2-/- mice were epicutaneously sensitized with OVA/SEB 
and after one-week resting period, mice received three intranasal OVA-challenges. 
7.5 Sample collection  
 
Mice were killed by isoflurane overdose 24 h after the last sensitization. Blood samples 
from the hepatic vein were taken for antibody analysis and skin biopsies from treated skin 
areas for RNA isolation and histology. In the asthma model, lung samples were collected 
for RNA isolation and for histological analysis. In the collection of bronchoalveolar 
lavage (BAL) fluids, the trachea
 
was surgically exposed, cannulated with a syringe, and 
flushed with 0.8 ml of PBS. Human skin biopsies were collected for RNA isolation and 
for histological analysis. 
7.6 RT-PCR 
Eurozol (EuroClone, Siziano, Italy) or Trizol (Invitrogen Life Technologies) were used to 
isolate RNA from skin biopsies or from cultured cells. The RNA content was measured by 
NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE). 
cDNA was synthesized from 0.5 μg of total RNA in 25 μl reaction mixture with High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). PCR 
primers and probes were obtained from Applied Biosystems and quantitative real-time 
PCR was performed with the 7500 Fast Real-Time PCR System and SDS Software v.1.4.0 
(Applied Biosystems). The gene expression between different samples was normalized 
with endogenous 18S rRNA, and the target gene expression was calculated by the 
comparative CT method according to the instructions of Applied Biosystems. 
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7.7 Histology and Immunohistochemistry 
Skin and lung biopsies were fixed in 10% buffered formalin and embedded in paraffin. 
Four µm sections from skin and lung specimens were cut and stained with haematoxylin 
and eosin (H&E). Skin sections were stained with o-toluidine blue for mast cell counting 
(I, II, IV), and lung sections with periodic
 
acid-Schiff (PAS) solution (IV) and examined 
under light microscopy (Leica DM 4000B, Wetzlar, Germany). BAL cell differentials 
were determined
 
on slide preparations stained with May-Grünwald-Giemsa (IV). 
 
For immunohistochemistry, mouse skin or lung specimens were embedded in Tissue-Tek 
oxacalcitriol compound (Sakura Finetek Europe B.V., Zoeterwoude, The Netherlands) and 
quick frozen on dry ice. Then 5-µm cryostat sections from
 
the skin and lung were 
prepared, air dried, fixed in acetone for 5 minutes,
 
and stored at –20°C. Primary anti-
mouse monoclonal antibodies were obtained from BD PharMingen (San Diego, CA). 
Biotin-conjugated secondary antibodies (anti-rat IgG (H+L) were purchased from Vector 
Laboratories Inc. (Burlingame, CA). 
 
Human formalin-fixed and paraffin-embedded skin samples (III) were first treated with 
hydrogen peroxide block (Thermo Scientific Cheshire, UK) to inhibit endogenous 
peroxidase activity. Slides were transferred into the Pretreatment Module (Thermo 
Scientific) in buffer at pH 9 (Thermo Scientific) to deparaffinise and perform heat induced 
antigen retrieval. Normal antibody diluent (Immunologic, Netherlands) was used to dilute 
primary antibodies, anti-human IL-33 antibody (Nessy-1, Alexis Biochemicals, San 
Diego, USA) and anti-human ST2 antibody (HPA007406, Sigma-Aldrich) or mouse mAb 
IgG1 isotype control (Cell Signaling, Danvers, MA, USA). After primary antibody, post-
antibody blocking solution (Immunologic bv) was used and slides were transferred to 
poly-HRP-goat anti-mouse/rabbit/rat IgG. AEC (Aminoethyl carbazole, Thermo 
Scientific) was used as the substrate. Samples were counterstained with Mayer's 
hematoxylin. 
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7.9 Flow cytometry (IV) 
Flow cytometry was performed using a CantoII instrument (Becton Dickinson, Fraklin 
Lakes, NJ) and the data was processed with the FlowJo Software (Tree Star, Ashland, 
OR). BAL fluids from epicutaneously OVA/SEB sensitized and intranasally OVA 
challenged WT and ST2-/- mice were stimulated with phorbol myristate acetate (20 ng/ml) 
and ionomycin (1 µg/ml), including brefeldin A (Sigma) at 37°C for 4 hours. After the 
stimulations, the cells were washed with cold PBS including 2 % FBS. Fragment 
crystallisable (Fc) receptors were blocked with an excess of anti-mouse CD12/32 
(eBioscience, San Diego) and surface stained with phycoerythrin-cyanine7 (PECy7)-
conjugated anti-CD3, fluorescein isothiocyanate (FITC)-conjugated TCRβ, phycoerythrin-
cyanine5 (PeCy5)-conjugated anti-CD4 and Alexa700-conjugated anti-CD8. Cells were 
permeabilized with intracellular Fix and Perm staining kit (Caltag, Burlingame, CA), and 
stained with PE-conjugated anti-IFNγ.  
7.10 ELISA 
Total and specific Ab levels were studied by the ELISA method. The standard BD 
Pharmingen protocol for sandwich ELISA was used to quantify the total amount of IgE ( 
I, II)  in the sera. Purified mouse IgE (clone C38-2; BD Pharmingen) was used as the 
standard. Plates were coated with rat anti-mouse IgE mAb (clone R35-37; BD 
Pharmingen), and bound IgE was detected with biotin-conjugated rat antimouse IgE (clone 
R35-118; BD Pharmingen). Streptavidin-HRP was purchased from BD Pharmingen and 
peroxidase substrate reagents from Kirkegaard & Perry Laboratories. 
 
OVA-specific IgE was measured by the straight ELISA method. In brief, plates were 
coated (50 µl/well) with 100 µg/ml OVA in 0.05 M NaHCO3 (pH 9.6) and incubated 
overnight at 4°C. Plates were washed with PBS-Tween 20 (0.05%) and blocked with PBS-
3% BSA for 2 h at 20°C and washed again. A volume of 100µl of diluted serum in 1% 
BSA-PBS was incubated at 4°C overnight. After washing, 2 µg of biotin-conjugated rat 
anti-mouse IgE mAb (clone R35-118) in 1 ml of 1% BSA-PBS was incubated for 2 h at 
20°C and washed again. Streptavidin-HRP (1:4000) in 1% BSA was incubated for 30 min 
  
 
 
55 
at 20°C. After washing, peroxidase substrate was added and absorbance read at 405 nm 
with automated ELISA reader (Titertek Multiscan; Eflab). 
 
OVA-specific IgG2a was measured by using the same method as described above. Plates 
were coated with 2 µg/ml OVA in 0.05 M NaHCO3 (pH 9.6). Serial dilutions of serum 
were used. Bound IgG2a was detected with biotin-conjugated rat anti-mouse IgG2a mAb 
(clone R19-15). SEB-specific IgE and IgG2a were measured by using the same protocol as 
for detecting OVA-specific IgE and OVA-specific IgG2a. Plates were coated (50 µl) with 
1 µg/ml SEB in 0.05 M NaHCO3 (pH 9.6). 
 
Commercial mouse IL-13 (R&D) and IFNγ (eBioscience) immunoassays were used to 
analyze IL-13 and IFNγ in the medium of stimulated LN cells (I). 
7.11 Western blot (III) 
A total of 20 μg of protein from whole lysed fibroblast extracts was separated on SDS-
PAGE and transferred onto Immobilon-P Transfer Membranes (Millipore). The 
membranes were stained with goat anti-human IL-33 (R&D) and incubated with HRP-
conjugated polyclonal rabbit anti-goat Igs (Dako Cytomation). Proteins were visualized in 
a Luminescent Image Analyzer (Image Quant LAS4000mini, GE Healthcare, Sweden). 
7.12 Luminex (IV) 
A Bio-Plex Pro Mouse Cytokine Assay (BioRad Laboratories, USA) was used for analysis 
of TNF-α, IL-13 and IL-5 proteins in BAL fluid supernatants according to the 
manufacturer's protocol with 3% BSA (Sigma-Aldrich, St Louis, MO) in PBS being added 
at a concentration of 0.5% to samples, controls and standards to ensure sufficient protein 
amounts for the assay. The assay was performed using Luminex xMAP Technology (Bio-
Plex 200 System, BioRad, Hercules, CA). 
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7.13 Determination of airway reactivity to methacholine (IV) 
Responses to inhaled methacholine (MCh) (Sigma-Aldrich, St. Louis, MO) were 
measured 24 hours after the last OVA challenge in conscious, unstrained mice using 
whole-body plethysmography (WBP, Buxco Research System, Wilmington). Briefly, 
mice were placed to into a chamber and exposed to nebulized PBS and to increasing 
concentrations of MCh for five minutes. After each nebulization, data recordings were 
taken for five minutes. AHR was expressed as enhanced pause (Penh) values, which were 
measured during each five minute sequence and were expressed for each MCh 
concentration as the increase of PenH as compared to baseline Penh values following PBS 
exposure (Hamelmann et al., 1997). 
7.14 Statistics 
The data were expressed as means (±SEM), and differences between means were analysed 
with Graph Pad Prism- software using a Student's t-test with a two-tailed test of 
significance. Mann–Whitney U-test was used when variances were different between 
groups for unpaired comparisons. Differences at P<0.05 were considered to be statistically 
significant. 
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8. RESULTS 
8.1 Effects of superantigen on experimental AD-model (I) 
The majority of patients with AD are colonized with Gram-positive bacterium S. aureus, 
and most of the patients are colonized with superantigen-producing strains. The 
immunological effects of S. aureus-derived enterotoxin SEB in AD were investigated in a 
murine model of AD. In this model, mice were epicutaneously sensitized with OVA-
allergen in the presence of SEB. OVA and SEB were also investigated separately. 
 
Topical SEB exposure without OVA-allergen induced skin inflammation with many 
features of AD-like inflammation. SEB induced infiltration of eosinophils (I, Fig. 1b), 
mast cells (I, Fig. 1c), CD4
+
 and CD8
+
 T cells (I, Fig. 2a) into the skin, and both Th1 and 
Th2 cytokines (I, Fig. 3) were upregulated in the skin after epicutaneous SEB-exposure. 
Similarly the numbers of SEB-specific TCRV β8+ cells (I, Fig. 2b) were increased in the 
SEB-sensitized skin. Moreover, SEB induced the production of SEB-specific IgE and 
IgG2a antibodies in the serum (I, Fig. 6). 
 
SEB together with OVA exacerbated skin inflammation, this being characterized by a 
thickening of the skin and infiltration of mast cells (I, Fig. 1) and T cells (I, Fig. 2a). The 
combination of OVA and SEB increased the expression of the Th2 cytokine, IL-13 and the 
Th1 cytokine, IFNγ as compared with OVA sensitization (I, Fig. 3). In addition, SEB 
increased the expression of proinflammatory cytokine-associated chemokines (CCL3 and 
CCL4), Th2-associated chemokines (CCL1, CCL11 and CCL17) and IFNγ-inducible 
chemokines (CXCL9, CXCL10 and CXCL11) (I, Fig. 4). In OVA-sensitized skin, CD4
+
 
cells were the major T cell population, whereas in the OVA/SEB-exposed skin sites the 
number of epidermal CD8
+ 
T cells was increased as compared to OVA-sensitized skin (I, 
Fig. 2a). OVA/SEB exposure increased the production of OVA-specific IgE and IgG2a, 
whereas less SEB-specific IgE was produced after OVA/SEB exposure as compared to the 
situation with SEB-exposure without the allergen (I, Fig. 6). 
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SEB and OVA stimulated LN cells were investigated after epicutaneous sensitization. 
SEB stimulation induced both IL-13 and IFNγ production, although the IL-13 production 
was higher after OVA stimulation. IFNγ was only produced in SEB stimulated LN cells 
derived from SEB or OVA/SEB sensitized mice (I, Fig. 5). 
8.2 Efficacies of topical drugs in a murine model of AD (II) 
At present, topical treatment schedules for AD involve corticosteroids and calcineurin 
inhibitors. A mouse model of AD was developed by repeated epicutaneous administration 
of OVA and SEB and these mice were used to evaluate the efficacy of topical drugs in 
AD. 
 
PBS and OVA/SEB were used as a model for epicutaneous sensitization. Betamethasone-
17-valerate, tacrolimus and cipamfylline treatments were tested in OVA/SEB and PBS 
sensitized skin sites. All of the investigated drugs reduced the thickness of the epidermis, 
whereas betamethasone and cipamfylline decreased both epidermal and dermal thickening 
(II, Fig. 1). The total number of skin-infiltrating inflammatory cells was decreased in all 
topically treated groups (II, Fig. 2a). Betamethasone was the most effective compound and 
it clearly decreased the numbers of eosinophils, mast cells, CD11c
+
 DCs, F4/80
+
 
macrophages (II, Fig. 2b-e) and both CD4
+
 and CD8
+
 T cells (II, Fig. 3) in the OVA/SEB 
sensitized skin. Similarly to betamethasone application of tacrolimus and cipamfylline 
also decreased the numbers of eosinophils and mast cells (II, Fig. 2b, c), whereas the 
numbers of DCs (II, Fig. 2 d), CD4
+
 cells and CD8
+
 cells (II, Fig. 3)  were only reduced 
by betamethasone and tacrolimus.  
 
Betamethasone and tacrolimus downregulated mRNA expression of IL-4, IL-13 and IFNγ. 
Cipamfylline decreased the expression of IFNγ, while the levels of the other cytokines 
remained unchanged. IL-10 mRNA expression was only downregulated by betamethasone 
when compared to the other investigated drugs (II, Fig. 4). 
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Finally, the concentrations of OVA and SEB-specific antibodies were investigated in the 
serum of topically treated and epicutaneously sensitized mice. Unexpectedly, tacrolimus 
and cipamfylline both significantly enhanced the levels of OVA-specific IgE, while 
betamethasone treatment had no effect on IgE or IgG2a antibodies. In addition, SEB-
specific IgG2a levels were reduced after tacrolimus or cipamfylline treatment (II, Fig. 5). 
8.3 Expression profiles of IL-33 and ST2 in AD after external 
triggering factors (III) 
IL-33 is one of the key cytokines which can induce the production of Th2 cytokines. Thus, 
the expressions of IL-33 and its receptors ST2 and IL-1RAcP were explored in human 
AD, in the murine model of AD, and in various cell models. In lesional skin of patients 
with AD, mRNA expression levels of ST2 and IL-1RAcP were upregulated as compared 
with nonlesional AD skin (III, Fig. 1a). In line with the ST2 results, the levels of TNFα 
and IL-13 mRNAs (III, Fig. 1b) were upregulated in the lesional skin as compared with 
nonlesional skin in patients with AD. Moreover, immunohistological staining of IL-33 and 
ST2 showed IL-33
+
 cells in the suprabasal keratinocytes and in endothelial cells (III, Fig. 
1c-f). The ST2
+
 cells showed positivity for the presence of infiltrating inflammatory cells 
in the dermis, and to some extent also in epidermis (III, Fig. 1g-j). 
 
Upregulation of ST2 and IL-33 mRNA in a mouse model of AD was confirmed with 
different models and kinetic study. Epicutaneous OVA sensitization significantly 
increased ST2 mRNA expression after three sensitization weeks. The mRNA expression 
of IL-33 was already upregulated after the first sensitization week (III, Fig. 2a). In line 
with the results of OVA sensitization, FLG-deficient mice without any exposure exhibited 
increased mRNA expression of ST2 and IL-33 at the age of 38 weeks (III, Fig. 2 b). 
Moreover, IgE + allergen stimulated mouse bone marrow-derived mast cells expressed 
both ST2 and IL-33 mRNAs (III, Fig. 2c). 
 
Different triggering factors in AD, including HDM and SEB were studied in human and 
mouse skin. AD patients with a history of HDM allergy were investigated after 2, 6, and 
48 hours of HDM-exposure. The mRNA expression levels of IL-33 and ST2 were 
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upregulated after 6 and 2 hours of HDM-exposure, respectively. The SEB patch test 
revealed slower upregulation of IL-33 and ST2 mRNAs compared with HDM and peaked 
24 hours of exposure (III, Fig. 3). In mouse studies, repeated epicutaneous exposure to 
SEB induced significant upregulation of ST2 and IL-33 mRNAs (III, Fig. 4a, b). In 
conjunction with the changes noted for IL-33 and ST2, mRNA expression levels of TNFα, 
IFNγ, IL-4 and IL-13 were increased in the skin (III, Fig. 4c-f).  
 
Moreover, the effects of topical application of betamethasone and tacrolimus on IL-33 and 
ST2 expressions were investigated. IL-33 and ST2 mRNAs were inhibited by tacrolimus 
treatment, whereas corticosteroid treatment had no significant effect on IL-33 or ST2 
expression (III, Fig. 5).  
 
The cellular sources of IL-33 and the cytokine environment needed for its expression and 
production were investigated in dermal fibroblasts, HaCaT keratinocytes, macrophages 
(III, Fig. 6a) and HUVEC endothelial cells (III, Supplementary figure S4) under 
proinflammatory conditions, Th2 conditions and Th1 favoring conditions. Furthermore, a 
combination of proinflammatory and Th1/Th2 cytokine stimulations was used. In all 
investigated cells, the combination of TNFα and IFNγ stimulation induced the expression 
of IL-33, and also the protein production of IL-33 in cultured primary dermal fibroblasts 
(III, Fig. 6c). In addition, the mimetic of double-stranded RNA further increased the 
cytokine induced IL-33 expression (III, Fig. 6 b,c). 
8.4 The functional role of ST2 in experimental AD and allergic 
asthma (IV) 
The murine model of AD was used to further characterize the role of ST2 in allergen and 
superantigen induced skin inflammation and allergic asthma. In the OVA/SEB sensitized 
skin, ST2-/- mice had increased numbers of neutrophils (IV, Fig. 1a), macrophages (IV, 
Fig. 2 a, j-m) and CD8+ lymphocytes (IV, Fig 2 a, f-i) compared with WT mice. In 
addition, mRNA levels of proinflammatory cytokines IL-1β and IL-6 were significantly 
enhanced in the skin of ST2-/- mice compared with WT mice (IV, Fig. 3a). In line with the 
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increased CD8
+
 infiltration into the sensitized skin, the expression levels of IFNγ were 
also upregulated (IV, Fig. 3a). Although IL-33 is reported to drive Th2 type inflammation, 
in the sensitized skin of ST2-/- mice, the mRNA expresson of Th2 cytokine, IL-5, was 
even slightly upregulated (IL-4 and IL-13 not statistically significantly) (IV, Fig. 3 b). 
 
Epicutaneously sensitized ST2-/- mice which were further intranasally challenged with 
OVA had a reduced number of eosinophils in the BAL fluid as compared with the WT 
controls (IV, Fig. 4a). In the lung tissue of sensitized ST2-/- mice, all Th2 type cytokines 
were downregulated when compared with WT at the mRNA level (IV, Fig 5a). 
Furthermore, the levels of the proinflammatory cytokine, TNFα and Th1 cytokine IFNγ, 
but not IL-6, were upregulated (IV, Fig 5 a,b). mRNA expressions of the regulatory 
cytokine IL-10 and the transcripton factor Foxp3 in the lung tissue of ST2-/- mice were 
increased (IV, Fig 5 c). Downregulation of Th2 cytokines was confirmed by the complete 
loss of IL-5 and IL-13 proteins in the BALF of ST2-/- mice compared with WT mice (IV, 
Fig 5 d).  
 
The BALF of sensitized WT and ST2-/- mice was analysed by FACS to confirm the 
increase in the numbers of CD8
+
 T cells and in the production of IFNγ. Similar to the 
results of immunohistochemistry data of CD8
+
 cells and mRNA expression data, ST2-/- 
mice possessed more CD3
+
CD8
+ T cells, which produced IFNγ (IV, Fig 6). 
 
Finally, the airway hyperreactivity to inhaled MCh was measured and it was similar in 
OVA-sensitized WT and ST2-/- mice (IV, Supplementary Figure S2). 
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9. DISCUSSION 
AD is a common skin disease with a high prevalence in the developing and already 
developed countries. The disease mechanisms in AD remain partly unknown and specific 
treatment options with fewer side effects are needed.  
 
SEB-producing S. aureus commonly colonizes the skin of patients with AD. Therefore, in 
the current study, the effects of superantigen on experimental AD-like skin inflammation 
were studied. Skin inflammation was severe and IgE production was increased after 
topical SEB exposure with allergen. SEB induced skin inflammation characterized by 
CD8
+
 and CD4
+
 T cells and a mixed Th1/Th2 response in the skin. When topical 
treatments with corticosteroid, calcineurin inhibitor and phosphodiesterase inhibitor were 
applied to allergen and SEB sensitized skin, the severity of inflammation declined. A 
corticosteroid and tacrolimus which are presently the first and second line of therapy in 
AD were the most efficient in healing the inflammation.  
 
Current research in the field of atopic diseases is very much concentrated on the 
epithelium. Furthermore, in this thesis, a newly described epithelial-derived cytokine, IL-
33, was investigated in AD. Expression profiles after external triggering factors were 
explored in experimental AD and in human patients. Both IL-33 and its receptor ST2 were 
upregulated in human and mouse skin after external triggering factors. Moreover, IL-33 
was already upregulated in the murine tape-stripped skin without any allergen exposure, 
indicating that the mechanical skin injury caused by scracthing of the skin increase the 
expression of IL-33. Although IL-33 has been reported to increase the production of Th2 
cytokines, especially IL-13 and IL-5, disruption of this pathway as achieved in ST2-/- 
mice did not downregulate the expression of Th2 cytokines in the sensitized skin. 
However, in the asthmatic airways of ST2-/- mice, there was downregulation of all Th2 
cytokines. These novel results suggest that the IL-33-ST2 pathway can be used to target 
the Th2 response in asthmatic airways. On the contrary, in AD skin, pathways other than 
ST2 are critical in the development of the Th2 response. The increased IL-33/ST2 
expression in AD skin may therefore act as an alarm signal of damaged tissue. 
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9.1 Topical SEB exposure induces AD-like skin inflammation and 
exacerbates allergen-induced skin inflammation (I) 
S. aureus is believed to play a significant role in AD and nearly 80 % of patients with 
severe AD produce superantigen specific IgE antibodies (Nomura et al., 1999). S. aureus 
can secrete various enterotoxins; SEA and SEB representing the most common 
superantigens in AD patients (Akiyama et al., 1996). SEB is believed to exert its effects 
through several mechanisms. It can bind to the MHCII-TCR complex or act through SEB-
specific antibodies (Leung et al., 1993). In addition, these bacterial toxins can alter the 
function of Tregs (Lin et al., 2011). 
  
A murine model of AD was used to investigate the effects of topical SEB exposure in the 
sensitized skin and systemic responses in skin-draining LNs and in the blood. Both CD4
+
 
and CD8
+
 T cells infiltrated into SEB sensitized skin, which supports the superantigenic 
properties of SEB. Unlike conventional antigens, superantigens can activate large numbers 
of T cells resulting in massive release of cytokines (Cardona et al., 2006; Laouini et al., 
2003; Sundberg et al., 2002). In line with the increased numbers of T cells in the SEB 
sensitized skin, the expression levels of both Th1 and Th2 type cytokines were highly 
upregulated. In the comparison of OVA sensitized skin and OVA/SEB sensitized skin 
sites it was found that the inflammation was more severe with the combination of allergen 
and SEB exposures. In the OVA sensitized skin, the skin infiltrating T cells were mostly 
CD4
+
 T cells, whereas the numbers of CD8
+
 cells were highly increased in OVA/SEB 
exposed skin sites. SEB alone increased the number of both CD4
+
 and CD8
+
 cells. 
 
CD4
+ 
T cells predominate and only a few CD8
+
 T cells can be detected in the skin of 
patients with AD (Simon et al., 2004). However, the atopy patch test with HDM has been 
shown to induce the recruitment of CD8
+
 T cells into AD skin and involved CXCL9 and 
CXCL10 chemokine expression (Hennino et al., 2011). In line with their results, topical 
SEB exposure elicited a major upregulation of epidermal CD8
+
 cells, and simultaneous 
increase of CXCL9 and CXCL10, i.e. chemokines which are known to be IFNγ-inducible. 
Similar to the situation with these chemokines, the expressions of IFNγ and IL-12p40 
were significantly inreased in SEB exposed skin with or without the allergen. Production 
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of IFNγ was also seen in SEB-stimulated LN cells from SEB-sensitized mice, which may 
due to SEB-specific T cells, most likely CD8
+Vβ8+ cells in the LNs. SEB has been 
reported to lead to the clonal expansion of SEB-reactive CD8
+
 Vβ8+ T cells in mice (Heeg 
et al., 1995; Marrack and Kappler, 1990). 
 
In addition to Th1 type response in the skin and LNs also Th2 type responses were 
upregulated in SEB-sensitized skin. Moreover, CCL1 and CCL8, which are known ligands 
for CCR8 were upregulated in the SEB sensitized skin. CCR8 has been shown to be 
critical in promoting Th2 cell homing into allergen-sensitized skin in a mouse model of 
AD (Islam et al., 2011). In addition, it has been shown that SEB can promote the 
migration of skin-homing T cells (Cardona et al., 2006). 
 
Topical SEB exposure increased OVA specific IgE and IgG2a antibodies in the serum. It 
also induced SEB specific IgE and IgG2a. According to the antibody results, SEB can act 
as a superantigen and also increase the effect of a conventional antigen. This might due to 
the binding site of SEB in the MHCII-TCR complex. SEB binds to the outside domain of 
the MHCII-TCR complex and does not require internalization and proteolysis. It might 
also affect the signal produced by a conventional allergen; binding of SEB to the outside 
domain of MHCII-TCR complex might allow at least some interaction to occur between 
the TCR and peptide-MHC complex (Dinges et al., 2000). 
 
This data stronly support the importance of eradication of S. aureus colonization in AD 
patients. S. aureus can exacerbate the inflammatory response in the skin by producing 
superantigens. Moreover, S. aureus is able to activate innate immunity by TLR2 which 
recognizes a variety of Gram
+
 bacterial products, such as peptidoglycan, lipoteichoic acid 
and lipoarabinomannan (Takeuchi and Akira, 2001). Therefore, the control of S. aureus 
colonization in therapeutic strategies might be beneficial in patients with AD. 
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9.3 A murine model of protein-induced skin inflammation is 
useful in studying efficacies of topical therapies in AD (II) 
The need for more effective AD therapies with less adverse effects has stimulated the 
research to develop new treatment possibilities. In some patients, AD is a life-long skin 
disease with an unpredictable disease activity and prognosis. Therefore, new treatment 
strategies are needed. A mouse model of AD was characterized, which can be used to 
evaluate new therapies in AD. The model was performed as described in I with OVA 
together with SEB, and the efficacy of topical administration of corticosteroid, tacrolimus 
and cipamfylline was studied. 
 
One-week topical application of a corticosteroid or calcineurin inhibitor significantly 
decreased the expression of Th2 type cytokines IL-4 and IL-13 and Th1 cytokine IFNγ. 
The number of eosinophils, mast cells, CD11c
+
, CD4
+
 and CD8
+
 T cells was also 
decreased in OVA/SEB sensitized skin after corticosteroid or tacrolimus therapy 
highlighting the reduced inflammatory reaction and the suitability of this model for 
investigating topical drugs in AD. The most beneficial drugs in the inhibition of the 
inflammation were those compounds which are already the first and second line of 
therapies in AD, such as corticosteroids and calcineurin inhibitors (Akdis et al., 2006). 
Betamethasone-17-valerate, known to be a powerful corticosteroid, has many beneficial 
effects on AD. However, local skin atrophy is a well-known adverse effect of 
corticosteroid treatment. All of the investigated drugs decreased the number of 
inflammatory cells in the sensitized skin as well as the thickness of the epidermis. 
Morover, the atrophic effect of corticosteroids was seen in betamethasone treated dermis, 
which was even thinner than the control treated skin. 
 
Corticosteroids suppress the inflammation by binding to glucocorticoid receptors (GR) in 
the cytoplasm which then dimerize and are translocated to the nucleus, where they bind to 
the glucocorticoid recognition sequence (GRE) on the promoter of glucocorticoid-
responsive genes finally inducing or repressing the gene. Moreover, GR may interact 
directly with other transcription factors, and may have effects on the chromatin structure 
(Barnes, 1998). Glucocorticoids are known to decrease the transcription of IL-1, IL-3, IL-
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4, IL-5, IL-6, IL-12, IL-13, TNFα and GM-CSF (granylocyte-macrophage colony 
stimulating factor). Suppression of Th2 type cytokines, IL-4 and IL-13, was detected after 
betamethasone or tacrolimus treatment. However, cipamfylline which is a type 4 
phosphodiesterase (PDE-4) inhibitor did not alter Th2 type cytokines in the sensitized 
skin, but decreased Th1 cytokine IFNγ. This might due to their different mechanisms of 
action. Tacrolimus achieves immunosuppression mainly by inhibiting T lymphocyte 
activation by inhibiting IL-2 transcription, which in turn represses T lymphocyte 
responsiveness to foreign antigens. Tacrolimus and its binding protein form a complex, 
which then associates with calcineurin, calcium and calmodulin, resulting in inhibition of 
calcineurin phosphatase activity, and finally controls the transcription of inflammation 
associated genes including IL-2, GM-CSF, TNFα and IFNγ. Cipamfylline is a potent and 
selective inhibitor of PDE-4, which is specific for cyclic nucleotide adenosine 3' 5' cyclic 
monophosphate, cAMP. It has been demonstrated that intracellular cAMP levels in atopic 
leukocytes are reduced by elevated cAMP-PDE activity (Grewe et al., 1982). Although 
cipamfylline was able to reduce the inflammatory reaction in the sensitized skin, its effects 
were milder than those achieved by either tacrolimus or betamethasone. Further studies 
are needed to clarify wheather the dosage of cimpamfylline was optimal and it should be 
taken into consideration when making comparisons between investigated drugs. 
 
Importantly, tacrolimus and corticosteroid treatments downregulated antigen and 
superantigen-inducd skin inflammation. In line with these findings, others have shown that 
S. aureus colonization can be erased with topical tacrolimus (Pournaras et al., 2001; 
Remitz et al., 2001) or corticosteroid (Nilsson et al., 1992; Stalder et al., 1994) therapies 
in human AD. On the contrary, some patients with AD do not seem to respond to 
corticosteroids alone. Staphylococcal superantigens might induce corticosteroid resistance, 
most probably by inducing the formation of the glucocorticoid receptor β-isoform. This 
receptor form antagonizes the activity of the glucocorticoid receptor α-isoform which is 
glucocorticosteroid-activated transcripton factor and cause modulations of corticosteroid-
sensitive genes. In addition, superantigens can activate mitogen-activated protein kinase 
/extracellular signal-regulated kinase (ERK) pathway, which phosphorylates the 
glucocorticoid receptor and inhibits nuclear translocation of this molecule and finally 
inducing corticosteroid resistance. However, these results show that short-term medication 
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with corticosteroid is efficient in the downregulation of the superantigen and antigen 
induced skin inflammation and one could speculate that corticosteroid resistance might 
develop during long-term therapy. 
 
The consentrations of allergen and OVA-specific antibodies in the serum were 
investigated after topical drug administration. Surprisingly, tacrolimus and cipamfylline 
increased OVA-specific IgE concentrations and decreased SEB-specific IgG2a 
concentrations, whereas betamethasone had no effect on IgE or IgG2a antibodies. In 
patients with AD, tacrolimus treatment was able to decrease serum IgE concentrations in a 
subgroup of patients with elevated serum IgE at the baseline level. However, in patients 
with a less favourable AD response to tacrolimus, serum IgE tended to increase (Virtanen 
et al., 2007). It should be also taken into account that mice were treated only for one week 
in comparison to the several month treatment schedules provided to human patients. It is 
also possible that an early increase in human patients also exists, but there is no data 
available after one week therapy with tacrolimus. 
 
Together, this data shows that the murine model of AD achieved by repeated epicutaneous 
sensitization with OVA together with SEB is valuable and reproducible model with which 
to investigate new topical medications in AD. 
9.4 IL-33 and ST2 signalling in AD and allergic asthma (III, IV) 
IL-33 is a newly described cytokine member in the IL-1 family. It has recently been found 
to participate in the epithelial alarmin defence system but its precise role in immunity is 
poorly understood; IL-33 might serve as a link between innate and adaptive immunity. 
There is evidence that IL-33 might have a critical role in innate immunity and furthermore 
it drives Th2 type responses and might be involved in allergic and atopic diseases, acting 
as a proallergic or pro-Th2 cytokine by binding to its specific receptor ST2 and a co-
receptor IL-1RAcP. Recent genetic studies have linked epithelial-derived IL-33 and its 
receptor ST2 to Th2-associated diseases, especially allergic asthma but also other allergic 
diseases (Moffatt et al., 2010; Ober and Yao, 2011; Shimizu et al., 2005). Therefore, the 
expression profiles of IL-33 and ST2 were characterized in Th2-associated disease, atopic 
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dermatitis after external triggering factors. The functional role of ST2 was further studied 
in a murine model AD and allergic asthma. 
 
The expression levels of IL-33 and ST2 were increased in the skin of patients with AD 
pointing to critical roles for these proteins in atopic skin inflammation. Consistent with a 
recent finding that IL-33 is upregulated in the tape-stripped human skin (Dickel et al.), the 
present results revealed increased expression of IL-33 in tape-stripped mouse skin. AD is 
clinically characterized by intense pruritus inducing scratching of the skin. Thus, when the 
skin is damaged by a mechanical trauma, especially by scratching of the skin, cell injury 
occurs. These necrotic keratinocytes release IL-33, which then activates ST2-expressing 
mast cells (Allakhverdi et al., 2007; Enoksson et al., 2011; Moritz et al., 1998), Th2 cells 
(Xu et al., 1998) and eosinophils (Cherry et al., 2008). In addition, recent findings have 
revealed ST2-expression also in CD8
+
 cells (Ngoi et al., 2012; Yang et al., 2011) and in a 
newly described innate type lymphoid cells called nuocytes (Bartemes et al., 2012; Kim et 
al., 2012). 
 
In addition to mechanical trauma, also external allergens and SEB induced the expression 
of IL-33 in human AD patients as well as in the mouse model of AD the same way as 
other cytokines e.g. TNFα, IFNγ, IL-4 and IL-13. IL-33 and ST2 were upregulated in the 
murine model of AD after epicutaneous OVA exposures, epicutaneous SEB exposures, 
and spontaneously in flaky tail (ft/ft) mice, animals which have a disturbed skin barrier. In 
human AD, the expression levels of IL-33 and ST2 were increased in the skin after atopy 
patch tests with HDM or SEB. These results highlight the important role of the IL-33-ST2 
interaction in AD when the skin becomes exposed and vulnerable to external allergens or 
bacterial infections. 
 
Moreover, the upregulation of IL-33 by OVA and SEB in the murine AD-like skin was 
suppressed after topical tacrolimus therapy. This might due to the downregulating effects 
of tacrolimus on IFNγ (II). We found that the combination of TNFα and IFNγ was 
essential for increased expression of IL-33 in dermal fibroblasts, keratinocytes and 
endothelial cell-lines and primary macrophages. Together these results seem to point to a 
possible mechanism to explain how topical SEB exposure increases IL-33 production. 
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SEB might activate T cells or APCs to produce IFNγ and TNFα resulting in enhanced 
expression of IL-33 in surronding fibroblasts, macrophages and keratinocytes. Moreover, 
increased concentrations of TNFα and IFNγ have been detected in the whole blood of 
patients with chronic AD (Vakirlis et al., 2011). 
 
Skin barrier dysfunction and defects in innate and adaptive immunity make an individual 
susceptible to bacterial and viral infections, which may further aggravate the 
inflammation. Therefore, we treated fibroblasts with a mimetic of double-stranded RNA 
and observed only a weak induction of IL-33, suggesting that viral exposure itself is not 
the primary triggering factor for IL-33. This is in line with a recent finding that human 
bronchial epithelial cells do not produce IL-33 when stimulated with dsRNA (Chustz et 
al., 2011). However, those fibroblasts which had been first stimulated with the 
combination of TNFα and IFNγ before dsRNA produced enhanced levels of IL-33, 
indicating that under certain disease conditions, viral infection may increase the 
transcription of IL-33. 
 
In an attempt to further clarify the role of ST2 in AD, the study was conducted with ST2-/- 
mice, which were epicutaneously sensitized with OVA and SEB. ST2-/- mice possessed 
more CD8
+
 cells and innate type cells in the skin as compared to WT controls. Even 
though the IL-33 pathway has been associated with Th2 responses, recent observations 
have revealed ST2 expression also in CD8
+
 T cells (Yang et al., 2011). Moreover, IL-33 
has recently been associated with protective antiviral CTL responses (Bonilla et al., 2012). 
It was found that in the absence of ST2, the numbers of CD8
+
 T cells are increased in the 
murine model of AD suggesting that ST2 might affect the function of CD8
+
 T cells. ST2 
may limit the innate immune response by acting on CD8
+
 cells and macrophages, as well 
as controlling the influx of neutrophils into the site of inflammation. 
 
Although IL-33 has been reported to increase the production of Th2 cytokines, loss of 
function in ST2 gene did not downregulate Th2 responses in the murine sensitized skin. 
Moreover, proinflammatory cytokines IL-1β and IL-6 as well as Th1 cytokine IFNγ were 
upregulated. These results suggest that under certain conditions, especially those related to 
innate immunity, ST2 may exert a protective or regulatory role (Turnquist et al., 2011) 
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and thus disruption of the ST2 pathway may even exacerbate the skin inflammation by 
inducing the production of proinflammatory cytokines and IFNγ. Moreover, IL-33 is also 
beneficial in certain condition and can help to clear pathogens (Liew, 2012). IL-33 can 
block the activity of G-protein-coupled receptor kinase 2 (GRK2). The expression of 
GRK2 normally leads to the inhibition of the expression of CXCR2 on neutrophils and 
reduces neutrophil migration. Therefore blockade of GRK2 by IL-33 can reverse this 
process, leading to the influx of neutrophils to the site of infection and achieving bacterial 
clearance. This protective role of IL-33 to promote increased bacterial clearance has been 
demonstrated in sepsis (Alves-Filho et al., 2010). 
 
Similar to the situation in sensitized skin, there was upregulation of IFNγ-producing CD8+ 
T cells in the lungs of epicutaneously sensitized mice. However, mRNA expression and 
protein production of Th2 cytokines were drastically downregulated in the BAL fluid and 
lung tissue of sensitized ST2-/- mice in line with the decreased number of eosinophils in 
the BALF of ST2-/- mice. Consistent with this finding, it has been demonstrated that the 
IL-33/ST2 signalling pathway can enhance the expression of CCR3, which is important in 
facilitating the mobilization of eosinophils from bone marrow to peripheral blood and the 
trafficking of these cells to the site of inflammation (Stolarski et al., 2010). Moreover, 
previous studies with ST2-/- mice have demonstrated downregulation of the Th2 
cytokines, IL-13 and IL-5, in the lung tissue of a mouse model of asthma obtained with 
intraperitoneal injections of OVA together with alum (Coyle et al., 1999; Kurowska-
Stolarska et al., 2008). However, in earlier studies, the expression of IL-4 was not 
decreased in ST2-/- mice. In our asthma model, ST2-/- mice, which were epicutaneously 
sensitized and intranasally challenged with OVA, displayed reduced expression of all Th2 
cytokines, IL-4, IL-13 and IL-5. Results obtained from ST2-/- mice are consistent with the 
downregulative effect of ST2 mAb on Th2 cytokines in the lung tissue of WT mice in 
Th2-dependent allergic asthma model (Lohning et al., 1998), pointing out that the results 
obtained from the lung tissue is not a consequence of general immune system failure in 
ST2-/- mice. 
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IL-33 may have been preserved during evolution as a part of the host defence against 
infection. Together these results suggest that the IL-33/ST2 pathway can regulate innate 
immune responses and CD8
+ 
cell mediated responses in the skin and airways of 
epicutaneously sensitized mice. In addition, the signalling pathway results in a complex 
range of biological functions with a tissue specific phenomenon. ST2 appears to be 
dispensable for the development of Th2 response in sensitized skin, whereas it is the main 
inducer of Th2 cytokines in asthmatic airways. These novel findings highlight that the Th2 
response in the lung tissue is totally blocked in the absence of ST2, indicating that IL-33-
ST2 pathway can be used to target the Th2 response in asthmatic airways. On the contrary, 
in AD skin, other pathways in addition to ST2 are critical in the development of Th2 
response. The increased IL-33/ST2 expression in AD skin may therefore act as an alarmin 
of damaged tissue. Disruption of this signal pathway may lead to unwanted exacerbation 
of skin inflammation in AD. These results open new avenues to understand and elaborate 
the basic mechanisms of allergic sensitization through the skin and the developing 
systemic response leading to asthmatic inflammation in allergen challenged lung tissue. 
9.5. Future directions 
S. aureus is one of the microbes in AD skin, but also other bacteria and other microbial 
compounds most likely play critical roles in skin homeostasis as well as in inflammatory 
conditions. Therefore, future studies to characterize the whole microbiome of the skin 
would provide novel information on skin associated diseases. The current study 
demonstrates the exacerbating effect of superantigen on allergen-induced skin 
inflammation. It is known that SEB acts by binding to the MHCII and TCR, however it 
would be interesting to investigate its possible binding to MHCI. There are few 
publications investigating this issue, although precise information remains unknown. 
 
Previously, there has not been any reproducible animal model available to test new topical 
treatment options in AD. Therefore, the model induced by epicutaneous allergen and SEB 
exposures can be now used to test novel drugs in AD before their efficacy is tested in 
human patients. 
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Future studies related to IL-33 and ST2 would be interesting and the different role of ST2 
in the skin and lung tissue should be further investigated. The mechanisms related to Th2-
inducing cytokines in the lung tissue in comparion to the skin would be interesting and 
useful, and future studies unravelling why the asthmatic airways but not AD-like skin of 
ST2-/- mice are protected from Th2 cytokines. Moreover, the precise role of IL-33 
signalling in nuocytes related to asthma and the investigation of nuocytes in AD would be 
worthy of exploration. 
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10. CONCLUSIONS 
This thesis has clarified the molecular pathomechanisms of AD and associated airway 
inflammation. In addition, the efficacy of a murine model of AD to test new topical 
medications was investigated. 
 
The murine model of AD was used to explore the role of superantigen, SEB, in AD-like 
skin inflammation. SEB alone induced CD4+ and CD8+ T cell infiltration into 
epicutaneously sensitized mouse skin, and promoted an AD-like skin inflammation 
characterized by eosinophils, mast cells and T cells in the skin. These inflammatory cells 
produced Th1 and Th2 cytokines. In addition, SEB raised IgE and IgG2a antibodies in the 
serum. Furthermore, when SEB was used together with the OVA-antigen, it augmented 
OVA-induced inflammation and increased the number of epidermal CD8+ T cells in the 
sensitized skin in comparison to OVA exposed skin, which was predominantly infiltrated 
with CD4+ T cells. The combination of OVA and SEB increased both IL-13 and IFNγ in 
the skin. In stimulated skin draining LN cells, IFNγ was produced only by SEB 
stimulation in LN cells derived from SEB or OVA/SEB sensitized mice. As a whole, this 
data shows that S. aureus derived superantigen, SEB is one of the bacterial components 
which exacerbates or induces skin inflammation in AD. Therefore superantigen-producing 
S. aureus colonization is an important aspect in AD and should be taken into consideration 
in therapeutic approaches in AD patients. 
 
The developed murine model induced by OVA and SEB was used to test topical drugs in 
AD. All of the investigated drugs, i.e. corticosteroid, tacrolimus and cipamfylline, reduced 
the thickness of the epidermis as well as inflammatory cell infiltrate. Those drugs which 
are already the first and second line of therapy in AD were the most beneficial in reducing 
the inflammation. Therefore, this murine model can be used to test new topical drugs. 
Earlier, no other reproducible mouse model of AD has been introduced in the context of 
topical therapies in AD. Moreover, tacrolimus and corticosteroid downregulated antigen 
and superantigen induced skin inflammation. Therefore, at least short-term medication 
with a corticosteroid is efficient in the healing of superantigen and conventional antigen-
induced skin inflammation. In conclusion, this model evoked by repeated epicutaneous 
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sensitization with OVA together with SEB proved to be valuable and reproducible model 
with which to investigate new topical drugs for treating AD. 
 
Recently, a new epithelial derived cytokine, IL-33 was found to be a ligand for the ST2 
receptor. Previously, the orphan ST2 receptor had been associated with Th2 type 
inflammation, although investigations of the role of ST2 in AD remained inconclusive. 
Therefore, we characterized IL-33 and ST2 expression profiles in AD after known 
external triggering factors and in the following studies the murine model of AD and 
exposed ST2-/- mice were investigated in greater detail. Further investigations were 
conducted with intranasal allergen challenges after epicutaneous sensitization, mimicking 
the atopic march. Although the expression levels of IL-33 and ST2 were upregulated in 
AD after SEB or HDM exposure as well as in FLG-deficient mice, in the mouse model of 
AD ST2-/- mice developed severe inflammation with high expression of Th2 type 
cytokines. However, epicutaneously sensitized ST2-/- mice which were further 
intranasally challenged with OVA-allergen, were totally protected from Th2 cytokines in 
the lung tissue. The specific mechanism behind this phenomenon is unknown and further 
studies will be needed to clarify the role of ST2 in different disease conditions. 
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